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Results! Why, man, I have gotten a lot of 
results. I know several thousand things that 
won’t work. 
 
Thomas A. Edison (1847-1931) 
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ABSTRACT 
 
Human pluripotent stem cells (including embryonic stem cells and induced 
pluripotent stem cells) are defined by two important characteristics: unlimited self-
renewal capacity and ability to switch on various differentiation pathways. These 
unique properties make them valuable tools for basic research and for the 
development of regenerative therapies. Since the discovery of stem cells, diverse 
culture conditions have been developed. Pluripotent stem cells are cultured either in 
the presence of feeder cells or with extracellular matrix components that together 
with growing colonies create a niche supporting the growth of undifferentiated cells. 
Current standard in vitro cell culture techniques are based on the use of xenogeneic 
reagents. However, this is not compatible with the clinical applications of human 
pluripotent stem cells. 
 
The aim of this study was to develop optimal culture conditions for pluripotent stem 
cells without the use of xenogeneic reagents, based on the analysis of their cell 
surface glycan expression.  
 
Initially, postnatal human feeder cells, foreskin fibroblasts, were shown to support 
the derivation of new embryonic stem cell lines and continued undifferentiated 
growth of these cells. However, the growth rate of stem cells was significantly lower 
on human feeder cells than on mouse embryonic fibroblasts. This feature restricts the 
use of human feeder cells for large-scale cell production of stem cells.  
 
Next, a number of human embryonic stem cell lines were derived and characterized 
in detail. The results show that despite of similar basic characteristics in the 
undifferentiated state, the differentiation capacity of stem cell lines varies. This 
highlights the need to identify markers that reliably predict cell lineage propensity of 
the stem cells lines. To identify such predictive markers we conducted a global 
analysis of cell surface glycans expressed on pluripotent human stem cells. The 
results show that embryonic stem cells have a unique glycan fingerprint that differs 
from their differentiated derivatives. This suggests that information of stem cell 
surface glycans can be used to design markers that define specific stages of 
differentiation. In addition, this information can be used to develop defined reagents 
for stem cell culture.  
 
Based on the analysis of stem cell surface glycans, specific glycan-binding lectins 
were studied for their capacity to support human pluripotent stem cells. This lead to 
 10 
the discovery of a lectin, Erythrina Cristagalli  (ECA) as a potent simple defined 
matrix for human pluripotent stem cells. This simple defined matrix, combined with 
a defined culture medium and the use of a Rho-kinase inhibitor at the time of cell 
propagation, allowed more efficient production of high-quality human pluripotent 
stem cells than MatrigelTM, the current standard acellular matrix used for stem cell 
culture.  
 
Taken together, these studies advance the development of technologies needed for 
the efficient generation of fully undifferentiated human pluripotent stem cells in 
defined conditions.  
 11 
1. INTRODUCTION 
 
Stem cells are present throughout life, from embryo to the adult. They are defined by 
their capacity for self-renewal and differentiation potential. Other cells in the body, 
do not have these abilities. According to their origin, stem cells are classified as 
embryonic, fetal, adult, or induced pluripotent stem cells. Fetal and adult stem cells, 
so called multipotent stem cells, are committed to specific developmental programs 
with limited self-renewal and differentiation capacity giving rise to only specific cell 
types. Stem cells in the fetus are needed for growth and maturation of the developing 
organs and tissues while the primary roles of adult stem cells in human are to 
repopulate the tissues by generating new mature cell types and regenerating 
damaged tissue in response to injury or disease (Choumerianou et al., 2008; Hipp 
and Atala, 2008; Pappa and Anagnou, 2009).  
 
Pluripotency is the capacity of a cell to divide and renew itself but also to develop 
into different cell types in the organism. These two features make pluripotent stem 
cells invaluable tools for studying developmental biology and various diseases.  The 
fertilised mammalian zygote enters the cleavage stage and divides several times and 
differentiates into outer trophoblast cells and the inner cell mass (ICM). Cell from 
ICM give rise to the pluripotent stem cells, embryonic stem (ES) cells. Current 
sources of human embryonic stem cells (hESCs) include excess embryos that would 
have been discarded after a successful in vitro fertilization process (Evans and 
Kaufman 1981; Martin 1981; Thomson et al. 1995; Thomson et al. 1998). However, 
the use of IVF embryos has created debates about the ethics of stem cell research, 
and alternative sources for hESC have been studied. A breakthrough came few years 
ago, when researchers managed to reprogram somatic cells into pluripotent state by 
transduction with regulatory transcription factors (Takahashi and Yamanaka 2006; 
Takahashi et al 2007; Yu et al 2007). These cells are called induced pluripotent stem 
cells (iPS). However, the development of iPS methods has not replaced totally the 
use of hESCs but has offered additional insight into the biology of cell 
differentiation, dedifferentiation, and aging in new biological models.  
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2. REVIEW OF THE LITERATURE 
2.1 PLURIPOTENT STEM CELLS 
 
Pluripotency means the potential of a cell to develop into all different cell types 
found in an embryonic and adult organism, excluding extraembyonic organs, such as 
placenta and umbilical cord. Stem cells possess also enormous capacity to self-renew 
and due to these two unique properties pluripotent stem cells are attractive sources 
for cell-based therapies and regenerative medicine. Five different pluripotent stem 
cell types have been characterized, embryonic carcinoma cells, embryonic germ 
cells, embryonic stem cells, induced pluripotent stem cells and adult testis-derived 
germline stem cells, (Figure 1). 
 
Figure 1. Origin of human pluripotent stem cells. Embryonic stem cells are derived from inner cell 
mass, embryonic germ cells from primordial germ cells and embryonic carcinoma cells are derived 
from teratomas. Induced pluripotent stem cells are reprogrammed from somatic cells and adult testis 
derived germ-line cells are dedifferentiated from spermatogonial stem cells. Figure modified from 
Eiges and Benvenisty 2002. Zygote and blastocyst images rights reserved VL-klinikat OY. 
 13 
2.1.1 Embryonic carcinoma cells (EC cells) 
 
Human pluripotent stem cells have also tumorigenic counterparts, embryonic 
carcinoma cells (ECs) (Evans and Kaufman 1981; Martin 1981; Thomson et al. 
1998), which are derived from gonadal tumors, teratocarcinomas. Teratocarcinoma 
consist of a mixture of differentiated cell types from all three embryonic germ layers 
(endoderm, mesoderm and ectoderm), as well as pluripotent cells, so called 
embryonic carcinoma cells (Martin and Evans 1975). ECs are usually aneuploid and 
often lack the ability to differentiate into well recognizable cell types even if some 
EC cell lines have been shown to differentiate quite well (Andrews et al. 1984; Pera 
et al. 1989; Andrews et al. 1990; Andrews et al. 1994). Numerous EC cell lines with 
variable differentiation capacity have been established. One of the best-characterized 
and most commonly used is NTERA2 (Andrews et al. 1984).  
 
2.1.2 Embryonic germ cells (EG cells)  
 
Human EG cells are isolated from primordial germ cells (PGCs) from embryonic 
gonads of five to nine weeks old fetuses (Shamblott et al. 1998). PGCs, the 
embryonic precursors of the gametes, undergo substantial epigenetic modifications 
resulting in erasure of imprints, genome wide demethylation, and in female foetuses 
X chromosomal reactivation. PGCs can be cultured at least for short periods as 
pluripotent stem cells (called embryonic germ cells (EG)), and they have been used 
to study human development. The importance of the EG cells as research material is 
currently moderately low.  
 
2.1.3 Embryonic stem cells:  from embryo to cell line 
2.1.3.1 Mammalian preimplantation development 
In normal mammalian development the presence of pluripotent stem cells is a 
transient phase during early embryonic development. Mammalian development is 
internal and the embryo receives nourishment from the mother. Embryogenesis starts 
after fertilization when the zygote has developed (Figure 2). Cleavage is a prolonged 
process from the early embryo to blastocyst implantation, and in comparison to non-
mammalian organisms, the mammalian cleavage process is measured in days rather 
than hours. During the first 3-4 days the embryo divides roughly once a day When 
the embryo consists of approximately 16 cells, it is called a morula. The morula 
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continues to divide and the blastocyst cavity begins to form. The blastocyst consists 
of two cell types, small inner cell mass cells (ICM) (Figure 2) and outer superficial 
layer cells called trophectoderm. As the blastocyst develops, the cells in both cell 
types divide and the cavity enlarges. Subsequently, ICM begins to develop into a 
two-layered structure. The first layer consists of columnar cells called epiblasts and 
the second layer that lies closest to the blastocyst cavity consists of hypoblasts. 
During further development patterning of the embryo depends on signals provided 
by hypoblast to the epiblast (Coucouvanis and Martin 1995; Brook and Gardner 
1997; Coucouvanis and Martin 1999). 
 
 
Figure 2. Embryo development from oocyte to blastocyst stage. A. Oocyte with one polar body. B. 
Fertilized oocyte, two pronuclei are seen in the middle. C. 4-cell stage embryo. D. Expanded 
blastocyst with clear and compact inner cell mass (ICM) and lots of cells in the trophectoderm. Image 
rights reserved VL-klinikat OY. 
 
Epiblast cells have developmental potential to differentiate into all different cell 
types in the body. During gastrulation the epiblasts migrate and give rise to the three 
embryonic layers: endoderm (giving rise for example to lung, liver, pancreas and 
intestine), mesoderm (heart, blood, vasculature and skeletal muscle) and ectoderm 
(neurons, skin). After gastrulation these three layers will continue to proliferate into 
various organ-specific precursors during the embryonic period of prenatal 
development (Gilbert 1994; Aplin 1996; Carlson 1999; Murry and Keller 2008). 
2.1.3.2 Derivation of Mouse ES and Epiblast stem cells 
Embryonic stem cells (ES) are pluripotent stem cells most often derived from the 
inner cell mass of blastocysts. During the transition from ICM to embryonic stem 
cells, the normal development is changed – the cells acquire the capacity for 
unlimited self-renewal while maintaining the capacity to differentiate into all three 
germ layers  (Tang et al. 2010). 
 
The first mouse ES cell lines were derived from mouse blastocysts independently by 
two groups (Evans and Kaufman 1981; Martin 1981). The mouse ES cells expressed 
all the mouse EC cell markers and were capable of differentiation in vivo and in 
 15 
vitro. The pattern of differentiation was essentially the same as for mouse EC cells. 
 
Mouse epiblast stem cells (EpiSCs) are isolated from the early postimplantation 
mouse embryo just after implantation but prior to gastrulation (Brons et al. 2007; 
Tesar et al. 2007; Najm et al. 2011). Mouse ES and EpiSC are two distinct 
pluripotent states, representing cells of the preimplantation embryo and later epiblast 
cells.  
2.1.3.3 Derivation of Human ES cells 
In vitro fertilization (IVF) may provide a couple, who has been otherwise unable to 
conceive, a chance to establish a pregnancy. In IVF technology, the egg cells are 
fertilized by sperm outside the body. The embryos are grown in laboratory up to 
four-cell or blastocyst stage, and then placed in the uterus (Edwards 1981; Edwards 
et al. 1981). In vitro culture of cells from human blastocysts was first described in 
the early 1980s, and it was suggested that these cells might have potential 
application in regenerative therapies (Fishel et al. 1984; Edwards 2001; Edwards 
2002).  
 
Subsequent growth of human embryonic stem (ES)-like cells for two passages with 
partial characterization was first described by Bongso and colleagues in 1994 
(Bongso et al. 1994), but the first permanent human embryonic stem cell (hESC) 
lines were reported in 1998 by Jamie Thomson’s laboratory (Thomson et al. 1998).  
hESC lines have most commonly been derived from surplus blastocyst stage 
embryos created through IVF (Thomson et al. 1998; Reubinoff et al. 2000) but also 
from embryos at different developmental stages (Strelchenko et al. 2004; Zhang et 
al. 2006; Feki et al. 2008) and from single blastomeres of cleavage stage embryos 
(Klimanskaya et al. 2006; Eiges et al. 2007).  
 
Although it seems that the hESC lines have a common genetic network of 
transcription factors that maintains them in a pluripotent state, there are reported 
differences between hESC lines. They may differ from each other in expression of 
several lineage markers (Abeyta et al. 2004; Rao et al. 2004; Ware et al. 2006; 
Adewumi et al. 2007). In female lines, variability has been shown in X-chromosome 
inactivation, inferred from X-inactive specific transcript (XIST) expression (Enver et 
al. 2005; Baker et al. 2007; Anguera et al. 2012). Reasons for differences between 
cell lines are still poorly understood. It has been discussed whether ES cells are 
trapped in development or if they are a result of culture conditions (Nichols et al. 
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2009). Recently a study (Tang et al. 2010) compared gene expression in single cells, 
following the development from the cells of the ICM through the outgrowth phase to 
the ES cell. Their results showed that the molecular signatures of undifferentiated ES 
cells are clearly different from cells of the ICM. Major changes were found in the 
expression of genes involved in the general metabolism, epigenetic regulators and 
also microRNAs. Human ES cells differ from mES but share defining features with 
the postimplantation epiblast state cells (EpiSCs), (Brons et al. 2007; Tesar et al. 
2007; Silva et al. 2008; Vallier et al. 2009; Sun et al. 2012).  
 
2.1.4 Induced pluripotent stem cells: from somatic cells to pluripotent cell line 
 
Somatic cells cannot divide indefinitely and this is critical for maintaining the 
integrity of their derivatives. However, somatic cells can be reprogrammed into 
pluripotent state by nuclear transfer where the oocyte nucleus is replaced with a 
nucleus derived from a somatic cell, resulting in genetically identical ESCs to the 
donor (Wilmut et al. 1997; Wakayama et al. 2001). So far, there are no published 
reports of successful derivation of cloned hESC lines by nuclear transfer. Pluripotent 
cells have been generated from somatic cells also by cell fusion (Cowan et al 2005; 
Kim et al. 2007) but these cells have had an abnormal karyotype and imprinting 
status (Yamanaka 2008). 
 
A breakthrough in reprogramming came when Takahashi and Yamanaka (Takahashi 
and Yamanaka 2006) selected 24 genes known to play a role in pluripotency, among 
them also genes known to be upregulated in tumors, and by using retroviruses 
introduced them into mouse fibroblasts. At the end of their studies they were able to 
produce ES-like cells from somatic cells by the ectopic expression of only four 
factors: Oct4, Sox2, Klf4 and c-Myc. These ESC-like cells showed similar results of 
pluripotency analysis than ES cells and they were named as induced pluripotent cells 
(iPS). First in the world, they (Takahashi et al. 2007) managed to reprogram human 
iPS cells from human dermal fibroblasts by using retroviral vectors, each carrying 
Oct4, Sox2, c-Myc, and Klf4, commonly called the Yamanaka factors. At the same 
time, another group (Yu et al. 2007) published very similar results of 
reprogramming. They used lentiviral vectors, each carrying Oct4, Sox2, Nanog and  
Lin28 to reprogram human fetal fibroblast to pluripotent stem cells. 
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Figure 3. Induced pluripotent stem cell procedure. Somatic cells, like fibroblasts, keratinocytes etc., 
are reprogrammed with transcription factors. During a few days cells start to change their 
morphology and form stem cell like colonies. The formed colonies are picked, cultured and 
characterized, and the cells that fulfill the criteria of pluripotency can be used for further studies. 
Modified from  Hussein and Nagy 2012 and http://rdnsystems.com. 
 
Later, pluripotent stem cells have been induced from many different cell types by 
using different cocktails of the transcription factors Oct4, Sox2, Klf4, Lin-28, Nanog 
and c-Myc (Yu et al. 2007; Aasen et al. 2008; Park et al. 2008b; Giorgetti et al. 
2009; Haase et al. 2009). Of these factors Oct4, Sox2, Nanog, and Lin-28 contribute 
to the reprogramming, and c-Myc and Klf4 enhance the efficiency of clonal recovery 
(Park et al. 2008a; Park et al. 2008b). Other factors have been identified that can 
replace the Yamanaka factors. Sox1 and Sox3 can replace Sox2, L-myc can replace 
c-myc, and Klf2 and Klf5 can replace Klf4 (Nakagawa et al. 2008).  
 
Reprogramming is an inefficient and stochastic process with long latency. All 
somatic cells may have the potential to generate iPS cells but adult cells have proven 
to be more difficult to reprogram back to the pluripotent state than newborn or 
embryonic cells (Park et al. 2008b; Hanna et al. 2009, Liebau et al 2012). Human 
iPSC lines, generated independently in different laboratories, show very similar 
morphology and gene-expression profiles than hESC but also some differences exist 
(Maherali et al. 2007; Chin et al. 2009; de Souza 2010). The reprogramming process 
is associated with high mutation levels in early passages of newly established 
hiPSCs, but during culture the mutation load decreases through a selection process 
(Gore et al. 2011; Hussein et al. 2011). It has also indicated that early passage iPS 
cells still retain a partial epigenetic memory characteristic of the somatic cell of 
origin, and that such memory can inﬂuence the differentiation potential of these cells 
(Kim et al. 2009; Polo et al. 2010). 
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Retroviruses integrate into the cell's genome and may activate or inactivate critical 
host genes. This is a major safety concern for iPS cells in regenerative medicine. 
However, iPS technology development has moved rapidly since its discovery, and 
many alternative strategies to generate iPS cells minimizing or eliminating 
permanent modifications of the genome have been generated (Figure 3), such as 
adenoviral vectors (Stadtfeld et al. 2008; Zhou and Freed 2009),  temperature-
sensitive Sendai virus (Fusaki et al. 2009; Ban et al. 2011), transient transfection 
(Brambrink et al. 2008; Okita et al. 2008), single plasmids (Kaji, Norrby et al. 2009), 
removable transposon systems (Woltjen et al. 2009; Yusa et al. 2009), episomal 
vectors (Yu et al. 2009), and recombinant reprogramming proteins (Kim et al. 2009; 
Shao and Wu 2010).  Moreover, the iPSCs can be established by the repeated 
administration of synthetic modified messenger RNA (Warren et al. 2010) and 
microRNA (miRNA) mediated reprogramming (Judson et al. 2009; Melton et al. 
2010). At this point of rapid development, it is not obvious what the optimal 
reprogramming method will be but it appears likely that efficient pluripotent 
reprogramming is feasible without major genetic side effects.   
 
2.1.5 Adult testis-derived germ-line stem cells 
 
There have been reports of the derivation of pluripotent ES cell-like cells from the 
human testes (Conrad et al. 2008; Golestaneh et al. 2009; Kossack et al. 2009; 
Mizrak et al. 2010).  In testes, the spermatogonial stem cells divide and differentiate 
to produce sperm but in pluripotent culture conditions in vitro, they can 
dedifferentiate to pluripotent ES-cell like cells. However, very recently, it has been 
shown (Chikhovskaya et al. 2012) that these cells share more features with 
multipotent human mesenchymal stem cells than pluripotent stem cells, but further 
research is required to assure the value of testis-derived germ-line stem cells. 
 
2.2 CULTURING PLURIPOTENT HUMAN STEM CELLS 
 
In vivo the pluripotent state is a transitory phase during early embryogenesis. The 
growth of pluripotent stem cells in in vitro conditions requires optimal balance 
between signals mediating cell survival, proliferation, and self-renewal. Most of the 
cells in the body need to attach to the extracellular matrix (ECM) in order to 
proliferate, migrate and differentiate, and even to survive. Human pluripotent stem 
cells (hPSCs) are not exceptions, they need either feeder-cells or extracellular matrix 
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coating, and, in addition, extrinsic signals from cell culture media to maintain 
pluripotency.  
 
Pluripotent stem cells tend to maintain tight contacts with their neighbors and grow 
in colonies. They survive poorly when dissociated into single cells and hence exhibit 
poor cloning efficiency. This makes protocols for culturing and differentiation less 
robust, as colony size and spatial distribution of colonies can affect signalling 
pathways in ESCs (Peerani et al. 2009).  For expansion of hPSC lines, it is crucial 
that cells maintain their undifferentiated state and their self-renewal capacity, and 
that they remain karyotypically normal. hPSCs are known to differentiate 
spontaneously if not kept under optimal culture conditions. Spontaneous 
differentiation can be induced by culturing hPSCs in suspension as aggregates, so 
called embryoid bodies (EBs), containing cell types from all three embryonic layers, 
endoderm, mesoderm and ectoderm (Thomson et al. 1995; Reubinoff et al. 2000; 
Odorico et al. 2001).  
 
In contrast to other primary cultures, in optimal conditions hPSCs appear to be 
immortal and show no evidence of either crisis or senescence. However, several 
studies have reported that prolonged culture of cells in vitro may lead to the 
accumulation of genetic and epigenetic alterations, such as point mutations, gene 
copy number variation, chromosomal aberrations and aberrant DNA methylation, 
(Buzzard et al. 2004; Draper et al. 2004; Maitra et al. 2005; Carpenter et al. 2009; 
Narva et al. 2010; Hussein et al. 2011). These events may provide selective 
advantage to cells grown under prevailing conditions by reducing tendency for 
apoptosis and differentiation capacity. The genetic changes associated with culture 
adaptation often occur in cancer associated regions, (Reya et al. 2001; Herszfeld et 
al. 2006; Baker et al. 2007), and hence adapted cells could also give insights into 
mechanisms of cancer progression (Gokhale and Andrews 2012). 
 
2.2.1 Feeder cell culture 
 
Long-term hPSC cultures have generally been performed on a feeder cell layer, 
which functions to support the undifferentiated growth of hPSCs. However, using 
feeder cells is highly laborious and limits large-scale hPSC production. In addition, 
the use of feeders introduces undefined and poorly characterized parameters to the 
system, thus increasing variability. 
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2.2.1.1 Mouse feeder cells 
On the basis of experience with mouse embryonic stem (mES) cells (Evans and 
Kaufman 1981; Martin 1981), the first human ES cell lines were cultured on 
mitotically inactivated mouse embryonic fibroblast (mEF) cells (Thomson et al. 
1998). They are primary cells derived from day 12.5–13.5 fetuses, and they do not 
continue to proliferate indefinitely. mEFs are used optimally between passages 3 to 
6, whereafter they begin to senesce and lose their capacity to support 
undifferentiated growth of hESC. Also immortalized mEFs (STO line) (Park et al. 
2003) have been produced and used successfully as feeder cells. 
 
The use of non-human materials bears a risk of transmitting pathogens, and they are 
not optimal in cultures aimed at cell transplantation in humans. For example,  human 
stem cells cultured on mouse feeder cells or in conditions that contain components of 
animal-origin have been reported to contain a significant level of N-
glycolylneuraminic (Neu5Gc) (Martin et al. 2005; Heiskanen et al. 2007). Humans 
have anti-Neu5Gc antibodies in the blood because this common mammalian sialic 
acid Neu5Gc is not synthesized in human cells. However, Neu5Gc expression in 
hPSC decreases upon culture in the absence of animal products (Heiskanen et al. 
2007).  
2.2.1.2 Human feeder cells  
Efforts towards a xeno-free environment have resulted in the generation of several 
types of human feeder cells, including fetal and adult muscle and skin cells 
(Richards et al. 2002), adult fallopian tube epithelial cells, and human foreskin and 
placental fibroblast cells (Hovatta et al. 2003; Genbacev et al. 2005). Also bone 
marrow-derived stromal cells have been used as feeders (Cheng et al. 2003). In 
addition, autologous, spontaneously differentiated hESC-derived fibroblast-like cells 
can be used (Xu et al. 2004; Stojkovic et al. 2005; Wang et al. 2005). 
  
The ability of different types of human feeder cells and cell lines derived from 
different mouse strains to support the undifferentiated growth of hESCs varies 
(Draper and Andrews 2002; Richards et al. 2003; Eiselleova et al. 2008). These 
variations in supporting the pluripotency and self-renewal of hPSCs can be attributed 
to the production of different types and amounts of secreted molecules. Comparing 
human and mouse feeder cells, human feeder cells (HFF) secrete Activin A and 
basic fibroblast growth factor (bFGF), which are known to be key factors in the 
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maintenance of the pluripotent state of stem cells, while mEFs secrete higher levels 
of Activin A but no bFGF at all. mEFs and HFFs secrete comparable levels of 
transforming growth factor beta 1 (TGFβ1), bone morphogenic protein 4 (BMP4) 
(Lim and Bodnar 2002; Prowse et al. 2005; Prowse et al. 2007; Eiselleova et al. 
2008), and laminin-511 (Hongisto et al. 2012) that are thought to play a supportive 
role in the maintenance of hPSC survival and pluripotency  (Miyazaki, et al. 2008; 
Evseenko et al. 2009; Vuoristo et al. 2009; Rodin et al. 2010) 
 
2.2.2 Feeder-free culture 
 
Maintenance of the undifferentiated stem cell phenotype in culture is not 
autonomous. It is dependent on the absence or inhibition of signals that stimulate 
differentiation. Together with extracellular matrix (ECM), the cell culture media 
should contain all necessary metabolites and nutrients to support either derivation or 
maintenance of hPSCs.  
2.2.2.1 Extracellular matrix 
The feeder layer provides important factors that suppress differentiation or promote 
self-renewal, and removal of the feeder cells will lead to differentiation. ECM 
consists of an organized, complex network of locally secreted macromolecules that 
govern many aspects of cellular behaviour, including proliferation and 
differentiation. In vitro growth matrices can be created from a variety of materials, 
both natural and artificial. Replacing feeder cells with defined human ECM 
components or synthetic biomaterials would be ideal for large-scale production of 
clinical-grade hESCs.  
 
The first feeder-free hESC culture used Matrigel and laminin-coating and mEF-
conditioned media. (Xu et al. 2001). Matrigel a soluble basement membrane extract 
from the Engelbreth-Holm-Swarm mouse tumor (Kleinman et al. 1982; Kleinman 
and Martin 2005), has been shown to support the culture of stem cells. It promotes 
the self-renewal and pluripotency of hPSCs. Matrigel contains mainly laminins, type 
IV collagen and enactin together with several growth factors such as bFGF, insulin-
like growth factor-1, epidermal growth factor, platelet-derived growth factor 
(PDGF), nerve growth factor and transforming growth factor-b1, and proteins related 
to the binding and signaling of growth factors (Hughes et al. 2010). In 2005 hESCs 
were propagated first time directly onto Matrigel (Klimanskaya et al. 2005). The 
growth factor reduced (GFR) version of Matrigel has been modified to reduce the 
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levels of these growth factors (Vukicevic et al. 1992) and is widely used in stem cell 
culture. The main disadvantage of Matrigel is that its composition varies from batch 
to batch and it contains animal components, making it unacceptable for clinical 
grade cellular products. 
 
It is difficult to elucidate the key interactions between cells and matrix because even 
single ECM proteins have multiple domains that can engage a variety of cell-surface 
receptors. Proteins such as laminins induce signals for promoting cell adhesion, 
growth, and migration. Laminins, the major components of the extracellular matrix 
of all basal laminae in vertebrates, are heterotrimeric glycoproteins forming 15 
different combinations in human tissues (Tryggvason 1993; Aumailley et al. 2005).  
They bind collagen and proteoglycans, and integrate with cellular domains through 
integrins and other receptors. Many groups have studied specific laminins in stem 
cell culture (Miyazaki et al. 2008; Evseenko et al. 2009; Vuoristo et al. 2009; Rodin 
et al. 2010), and laminin-511 and laminin-521 have been shown to support growth of 
undifferentiated stem cells (Vuoristo et al. 2009; Rodin et al. 2010). Also other ECM 
proteins, such as fibronectin (Amit et al. 2004) and vitronectin (Braam et al. 2008), 
have been shown to support hESCs at least to some extent. These proteins carry the 
Arg-Gly-Asp (RGD) cell recognition sequence, which is recognized by integrins and 
mediates cell adhesion. However, none of these recombinant proteins are currently 
commonly used in routine stem cell culture, at least partly because of their high cost. 
 
Synthetic materials could theoretically be an optimal solution as a stem cell matrix, 
because of reduced costs and elimination of possible hazardous contaminants. A 
synthetic chemical matrix based on the RGD sequence has been developed for hESC 
culture (Kolhar et al. 2010). Several commercial cell culture matrices are available. 
However, none of them has yet replaced MatrigeTM in common use. 
 
The complex carbohydrates at cell surface play an essential role in the specificity of 
cell-cell interaction and cellular adhesion. Lectins, the carbohydrate-binding 
proteins, occur ubiquitously in nature and are abundant in all living organisms from 
bacteria to mammals. They serve many different biological functions from the 
regulation of cell adhesion to glycoprotein synthesis.  They have been reported to 
enhance cell adhesion, growth and cell spreading (Grinnell and Feld 1979; Hughes et 
al. 1979; Rauvala et al. 1981; Rauvala and Hakomori 1981; Sanford and Harris-
Hooker 1990; Blasco et al. 1995). The reported effects on cell proliferation have 
been specific for cell and lectin type. This suggests that specific interactions between 
lectins and cell surface glycans are key players in the potential growth support. In 
 23 
hPSC research, lectins have been used for identification of pluripotent or 
differentiation stages (Wearne et al. 2006; Wearne et al. 2008; Toyoda et al. 2011; 
Wang et al. 2011), preferably based on exact data of stem cell glycans (Satomaa et 
al. 2009; Liang et al. 2010; Liang et al. 2011). 
2.2.2.2 Soluble components 
The cell culture media is used to provide necessary nutrients and metabolites for the 
maintenance of hPSCs. Both fetal bovine serum (FBS) and human serum (HS) have 
been used in culture media with feeder cells as well as in feeder-conditioned 
medium. The development of a serum alternative, the Knockout™ serum 
replacement (KO-SR), provided more standardized and defined culture conditions 
compared to serum-containing conditions. The mouse ES cell culture is depending 
on a lymphoid factor (Leucemia Inhibitory Factor, LIF), which promotes long-term 
maintenance of undifferentiated ESs by suppressing spontaneous differentiation 
(Smith et al. 1988; Williams et al. 1988). However, LIF is not essential to maintain 
the undifferentiated growth of hPSC or mEpiSC culture. Media containing KO-SR 
supports the prolonged growth of hPSCs in an undifferentiated state, with a higher 
growth rate and cloning efficiency than in serum-containing medium (Richards et al. 
2002; Richards et al 2003; Amit et al. 2004; Koivisto et al. 2004). To understand the 
molecular mechanisms and signals, which maintain self-renewal of undifferentiated 
hPSCs, it is necessary to develop more defined culture systems. Over the last few 
years, a number of molecular factors and signalling pathways that play a major role 
in maintaining hPSC self-renewal have been identified (Table 1).  
 
The FGFs are capable of eliciting a wide range of cellular responses such as 
proliferation, migration, differentiation, cell cycle arrest and self-renewal of hPSCs 
(Basilico and Moscatelli 1992; Hondermarck et al. 1994; Boilly et al. 2000; Kim, 
Cheon et al. 2005 Amit et al. 2004; Wang et al. 2005; Xu et al. 2005a; Xu et al. 
2005b). FGF2, also known as bFGF, in particular is an essential component for the 
maintenance of hPSCs and withdrawal of bFGF (Kim et al. 2005) or inhibition of 
signalling through FGF receptors (Dvorak et al. 2005) results in hPSC 
differentiation. The exact molecular mechanisms linking FGF-signalling with 
pluripotency are actively studied. Recently, it was proposed that FGF signaling 
through ERK phosphorylation directly regulates OCT4 and associated proteins that 
establish and maintain pluripotency (Yu et al. 2011; Brumbaugh et al. 2012).  
 
Many signals have been implicated in governing pluripotent stem cell fate together 
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with bFGF via direct and indirect mechanisms. The TGFβ growth factor family is of 
particular importance. Activin and nodal signalling activates the SMAD2/3 pathways 
(Xu et al. 2008; Vallier et al. 2009). SMAD2/3 bind to the promoter of the NANOG 
gene and activate its expression. Activation of SMAD2/3-mediated signalling or 
FGF2-mediated signalling also suppresses BMP4 expression in human ES cells. In 
contrast, BMPs activate SMAD1/5/8 pathways, which inhibit NANOG expression in 
human ES cells (Xu et al. 2008) and induce differentiation (Greber et al. 2007). 
TGFβ-superfamily member GDF3, which is highly expressed in pluripotent stem 
cells in mice and humans (Pera et al. 2000; Skottman et al. 2005), blocks the BMP-
mediated induction of differentiation and thus supports the maintenance of 
pluripotency marker expression in human ES cells (Chen et al. 2006).  
 
Table 1. Basic factors in undifferentiated stem cell culture  
Factor mES mEpiSC hPSC hEC 
LIF + - - - 
BMP4 + - - - 
Activin A and/or 
Nodal 
- + + - 
FGF 2 - + + - 
+ the indicated growth factors are required for self renewal 
- the indicated growth factors are not required for self renewal 
 
Wnt signaling is known to play a role in pluripotency and self-renewal as well as in 
differentiation of both mouse and human ES cells. It is not required for self-renewal 
but canonical Wnt signalling is likely to promote the balance between self-renewal 
and differentiation in hPSCs. However, there is disagreement about  the exact role of 
Wnt -mediated signalling in pluripotent stem cells (Sato et al. 2004; James et al. 
2005; Sumi et al. 2008; Villa-Diaz et al. 2009; Blauwkamp et al. 2012; Davidson et 
al. 2012).  
 
The first defined, completely animal-component free culture medium for hESC 
contained a combination of small molecules and proteins including bFGF, TGF-β1, 
litium chloride (LiCl), gamma-aminobutyric acid (GABA), and pipecolic acid. The 
cells were cultured on a matrix consisting of human collagen IV, vitronectin, 
laminin, and fibronectin (Ludwig et al. 2006). Several laboratories have designed 
completely defined culture conditions (Ludwig et al. 2006; Rajala et al. 2007; 
Akopian et al. 2010) and currently there are also many commercially available 
media. There is a lot of heterogeneity of culture conditions and also a lot of variety 
in the concentrations of growth factors in sustaining undifferentiated growth of 
hPSC. This reflects the fact that knowledge about the maintenance of self-renewal 
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and pluripotency of hPSC is still inadequate. 
2.2.2.2.1  Stem cell fate compounds 
Compounds that can bias the fate decision of stem cells have a long history in 
research, for example retinoic acid has been used to induce differentiation of both 
mouse and human embryonal carcinoma cells for over 30 years (Strickland and 
Mahdavi 1978; Andrews 1984). Small molecules, which can promote survival of 
hPSCs, have been successfully applied. Y-27632 (Watanabe et al. 2007) and 
pinacidil, an agonist of ATP-sensitive potassium channels, (Barbaric et al. 2010; 
Barbaric et al. 2011) inhibit Rho-kinase (ROCK) in vitro. ROCK is mainly involved 
in actin cytoskeleton rearrangement by promoting the stabilization of filamentous 
actin and triggers a signalling cascade that leads to coupling of actin–myosin 
filaments to the plasma membrane, resulting in actin–myosin contractility. Both 
pinacidil and Y-27632 promote survival of dissociated hPSCs by preventing 
apoptosis and increasing clonogenic capacity and hence can control human stem cell 
fates (Leung et al. 1996; Watanabe et al. 2007; Martin-Ibanez et al. 2008; Krawetz et 
al. 2009). 
 
2.3 CHARACTERISTICS OF PLURIPOTENT STEM CELLS 
 
hPSC cultures are complex mosaics of various cell types that cover the spectrum 
from self-renewing undifferentiated stem cells to incipient lineage-biased cells. The 
commitment of pluripotent cells to self-renewal or differentiation involves multiple 
genes and pathways and understanding the mechanisms controlling the status of 
hPSCs is a major challenge (Brivanlou and Darnell 2002). 
 
2.3.1 Morphological characterization  
 
Human pluripotent stem cell morphology is unique: they have a high nucleus to 
cytoplasm ratio, prominent nucleoli, and distinct colony morphology in epithelial 
cell-like colonies (Thomson et al. 1998; Reubinoff et al. 2000) (Figure 4). In 
addition, undifferentiated pluripotent cells have a distinctive nuclear architecture 
(lamina, nuclear speckles and heterochromatin domains) as well as chromatin 
structure (Meshorer and Misteli 2006). During differentiation, major changes in 
cellular morphology occur fast. After reprogramming many iPS colonies appear 
morphologically similar to ES cells but only a subset of these have comparable 
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molecular and functional features. Specific molecular and functional characterization 
is needed to distinguish fully reprogrammed iPS cells from those morphologically 
similar cells that are only partially reprogrammed and cannot form stable stem cell 
lines. 
 
Figure 4. Undifferentiated morphology of pluripotent cells and colonies. Pluripotent cell colonies 
have sharp edges (A) and cells in the colonies are round with clear nucleoli (B). Scale bar 100 µm. 
 
2.3.2 Cellular characterization 
 
Crucial biological phenomena are mediated through carbohydrates that are displayed 
on the surface of each cell. The outmost layer of mammalian cells is covered with a 
dense layer of glycans, called the glycocalyx (Figure 5), which is comprised of 
glycoconjugates (glycoproteins, glycolipids, and proteoglycans). As glycosylation of 
individual cells changes during cell development and differentiation, the glycocalyx 
is characteristic to every individual  cell type (Priatel et al. 2000; Moody et al. 2001; 
Comelli et al. 2006). The composition of the glycocalyx provides information used 
in cell recognition and in interactions with neighbouring cells and the environment 
(Varki A et al. 1999; Helenius and Aebi 2004). 
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Figure 5. Schematic picture of glycogalyx. A dense layer of glycoconjugates cover all cells. 
Modified from Lanctot et al 2007.  
2.3.3  Cell surface glycosylation 
 
Glycans are considered to be some of the most structurally varied molecules in 
nature. Glycosylated structures on the cell surface have a role in cell adhesion, 
migration and proliferation (Duksin and Bornstein 1977; Sharon and Lis 1989; Arndt 
et al. 2011) and they vary considerably between species. Glycosylation is the most 
common posttranslational modification in proteins and lipids (Apweiler et al. 1999). 
The pattern of glycosylation cannot be predicted directly from gene expression 
because of the complex enzymatic machinery of glycosylation and also because of 
the variable availability and transportation of monosaccharides. Change in the 
activity of a single glycan biosynthetic enzyme may have drastic effects on the 
appearance of the cell, and a change in the expression of one glycan modifying gene 
may modulate multiple glycoproteins at once (Comelli et al. 2006).  
 
There are two major types of glycosylation. In O-glycosylation the sugar is bound to 
the hydroxyl of a serine (Ser) or a threonine (Thr) residue. In N-glycosylation the 
sugar is attached to the amide group of an asparagine (Asn) residue in the consensus 
sequence Asn-X-Ser/Thr, where X represents any amino acid but proline (Petrescu et 
al. 2004). N-glycosylation affect many properties of glycoproteins (including their 
conformation, antigenicity, solubility, and recognition by glycan-binding proteins. 
Human N-glycans can be divided into biosynthetic groups of high-mannose-type, 
hybrid-type, and complex-N-glycans based on the amount and type pf glycan 
modification they have gone through (Figure 6) (Kornfeld and Kornfeld 1985; 
Schachter 1991).  
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Figure 6. Overview of three N-glycan subtypes: high-mannose, hybrid and complex. Glycosidic 
linkages are indicated by lines connecting the monosaccharides, and arrows indicate the 
locations of branch formation in N-glycan diversification, not all of which occur in any single 
N-glycan. Modified from Essentials of glycobiology (Varki A, Cummings R et al. 1999). 
 
Glycosylation takes place in the rough endoplasmic reticulum (RER), where a 
carbohydrate core is added to a newly synthesized protein. The protein is then 
transported from the ER to the Golgi apparatus (Yarema and Bertozzi 2001; Lowe 
and Marth 2003), where different intracellular, Golgi membrane-bound 
glycosyltransferases catalyse further reactions for growing oligosaccharide chains 
by using nucleotide sugar precursors as substrates (Baenziger 1994). Terminal 
epitopes, such as fucose residues or sialic acid, are added at the capping phase of 
the biosynthesis pathway by glycosyltransferases to bring more structural diversity 
to N-glycans. Fucosylation and sialylation are common types of glycosylation on 
the cell surface (Traving and Schauer 1998; Becker and Lowe 2003) and these 
modifications are critical also during embryogenesis and somatic stem cell 
differentiation (Landmesser et al. 1990; Shi and Stanley 2003; Xia et al. 2004). The 
glycosphingolipid composition changes during the differentiation of human 
embryonic stem cells and there are changes in the expression of specific 
pluripotency-associated glycosyltransferases (Chang et al. 2008; Satomaa et al. 
2009; Liang et al. 2011; Wang et al. 2011). Fucosyltransferases, encoded by FUT 
genes, catalyse the transfer of fucose to terminal positions of glycolipid and 
glycoprotein carbohydrate groups. So far, nine human FUT genes that encode 
fucosyltransferases acting on N-glycans have been identified (Javaud et al. 2003). 
During hESC differentiation into EBs, the expression of FUT1, FUT4 and FUT8 
disappears (Skottman et al. 2005; Satomaa et al. 2009; Hasehira et al. 2012) 
 
Sialic acids are transferred to carbohydrate residues by sialyltransferases that 
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comprise a family of enzymes. During hESC differentiation into neural progenitor 
cells the expression of sialyltransferases ST3GAL1, ST3GAL5 and ST8SIA1 is up-
regulated when compared to undifferentiated cells and, during definite endodermal 
differentiation, the expression of these sialyltransferases is down-regulated (Wang et 
al. 2011). These recent findings suggest that certain types of posttranslational 
glycosylation of cell surface proteins may reveal important information about 
transitions between pluripotent and differentiated states that occur during 
differentiation of pluripotent cells. 
 
2.3.4 Cell surface antigens 
 
Cell surface antigens have been long used to identify and purify specific cell types 
from blood and the immune system (Boyse et al. 1969) and since then they have 
played a key part in dissecting complex developmental systems. Human PSCs and 
ECs as well as mouse EpiSCs express a similar pattern of pluripotency associated 
cell surface antigens that are widely used to characterize the cells. Most of the 
commonly used cell surface antigens are glycoproteins or glycolipids (Kannagi et al. 
1983a; Kannagi et al. 1983b; Andrews et al. 1984a; Andrews et al. 1984c). 
Regardless of the long history of these surface antigens, their biological functions 
are poorly understood.  
 
Generally, a panel of surface antigen markers is used to monitor the differentiation 
status of hPSCs (Table 2) (Adewumi et al. 2007). Pluripotency associated cell 
surface markers that have been traditionally used to characterize hPSCs include 
tissue non-specific alkaline phosphatase markers Tra 2-49 and Tra 2-54, a high 
molecular weight antigen GCTM2, cell surface glycoprotein epitopes Tra-1-60 and 
Tra-1-81, glycosphingolipid antigen H type 1 and the stage-specific embryonic 
antigens SSEA-3 and SSEA-4.  
 
The tissue non-specific alkaline phosphatase (AP) is expressed at high levels in all 
human pluripotent stem cells (hEC, hEG, hES and iPSC) and its expression levels 
decrease following stem cell differentiation.  (Thomson et al. 1995; Shamblott et al. 
1998; Takahashi et al. 2007). The expression of AP is usually monitored either by 
Tra 2-49 and Tra 2-54 antibodies or using enzymatic histochemistry. 
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Table 2. Most commonly used stem cell surface markers in pluripotent stem cell analysis. 
Stem cell surface 
markers 
mES mEpiSC hPSC hEC 
SSEA-1 + + - - 
SSEA-3 - + + + 
SSEA-4 - + + + 
Tra 1-60 + + + + 
Tra 1-81 + + + + 
GCMT 2  + + + 
H-type 1 NE NE + NE 
Tra 2-49 + + + + 
+ the surface marker is expressed  
   -  the surface marker is not expressed 
   NE not exminated 
 
The high molecular weight antigen GCTM2 is associated with a cell surface keratan 
sulphate core molecule (Pera et al. 1988). Tra 1-60 and Tra 1-81 were earlier thought 
to recognize glycan epitopes of the same proteoglycan as GCTM2 (Badcock et al. 
1999; Schopperle and DeWolf 2007) but recently it was shown that Tra-1-60 and 
Tra-1-81 may recognize type 1 lactosamine epitopes rather than keratan sulphate 
(Natunen et al. 2011). However, the exact molecular identity of Tra-1-60 and Tra-1-
81 is still unknown.  
 
Glycosphingolipids (GSLs) are biological building blocks that contain lipid and 
sugar residues with sphingosine attached on the cell membrane (Svennerholm 1980; 
van Echten and Sandhoff 1993). GSLs are key molecules required for many cellular 
processes like cell-cell and cell-matrix adhesion and differentiation (Fredman 1993; 
Varki 1993; Hemmoranta et al. 2007; Hakomori 2008; Satomaa et al. 2009a; 
Satomaa et al. 2009b). The presence or relative abundance of individual gangliosides 
may vary during the development but the major changes take place at the level of 
different GSL series. All GSLs are synthesized from a common precursor, 
lactosylceramide, via various biosynthetic pathways resulting in so-called lacto-
series, globo-series and a-series ganglioside structures. All of these have been 
identified as pluripotency-associated GSLs (Figure 7.) (Satomaa et al. 2009b; Liang 
et al. 2010; Liang et al. 2011; Wang et al. 2011)  
 
Lactoseries GSLs  (Figure 7) were found in pluripotent stem cells quite recently 
(Liang et al. 2010; Liang et al. 2011).  Of these the H antigens are fucosylated 
glycan units that are direct substrates for glycosyltransferases giving rise to A, B and 
Lewis blood group antigens. Lacto-series H-type I determinant (fucosyl Lc4Cer) is 
present in undifferentiated PSCs and it disappears during differentiation. This is 
apparently due to the reduction in fucosyltransferase FUT1/FUT2 expression (Liang 
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et al. 2010).  
 
Of the globoseries glycolipids (Figure 7) SSEA-3 and SSEA-4 are among the most 
commonly used markers in identifying hPSCs. In mouse, SSEA-3 and SSEA-4 are 
expressed at cleavage stage embryos until morula stage but are absent from ICM and 
ES cells.  In contrast, in human they are present in ICM and ES cells but are absent 
at earlier stages and their expression decreases rapidly upon differentiation 
(Andrews et al. 1982; Damjanov et al. 1982; Shevinsky et al. 1982; Thomson et al. 
1998; Reubinoff et al. 2000). SSEA-3 is a precursor molecule to SSEA-4 and Globo-
H. The sialylgalactosylgloboside SSEA-4 is a sialylated derivative of SSEA-3 and 
Globo-H  (fucosylgalactosylgloboside) is a fucosylated derivative of SSEA-3. The 
most commonly used anti-SSEA-4 antibody (clone MC813-70) recognizes the latter 
globo-series structure but it also cross-reacts with a-series gangliosides GD1a and 
GM1b (Kannagi et al. 1983a; Kannagi et al. 1983b) that are shown to be present not 
only in undifferentiated cells but also in differentiated cells (Liang et al. 2010; Liang 
et al. 2011). This suggests that SSEA-4 (clone MC813-70), even if widely used, is 
not an optimal marker for undifferentiated stem cells.   
 
It has been shown that SSEA3/4 negative stem cells have not lost their pluripotent 
differentiation capacity (Enver et al. 2005; Brimble et al. 2007) demonstrating that 
SSEA-3 and SSEA-4 are not essential for the maintenance of hPSC pluripotency. 
However, these antigens may play a role in embryonic development. SSEA-3 and 
SSEA-4 antigens belong to P-blood group system. Rare pp and pk individuals lack P 
antigen (Gb4) and therefore also SSEA-3 and SSEA-4 antigens on their erythrocytes 
(Tippett et al. 1986). Women with this rare phenotype have a higher risk of 
spontaneous early abortion suggesting that SSEA-3 and SSEA-4 may play an 
important role in early development (Race RR 1975). 
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Figure 7. Illustration of the biosynthetic pathways leading to human stem cell specific GSL profiles. 
Globoseries and lactoseries GSLs are expressed on undifferentiated human ES cell membranes. 
Ganglioseries GSL are expressed mostly on differentiated hESCs even if some are found also on 
undifferentiated cells (Mikkola et al. unpublished data). The neo-lactoseries GSL, Lewis X, is 
expressed only on differentiated hESCs.  
 
One important aspect in the characterization of stem cell quality is to assess the lack 
of markers for early differentiation. Undifferentiated hPSCs should not express the 
neo-lactoseries oligosaccharide antigen SSEA-1. SSEA-1 (also known as Lewis X 
and CD 15) is a terminal carbohydrate epitope, both on glycolipids and 
glycoproteins. This epitope is related to Lewis blood group antigens and is found in 
a variety of embryonic and adult tissues and cancers.  As well as the globoseries 
glycolipid SSEA-3, also SSEA-1 expression pattern differs between human and 
mouse embryonic cells. In early embryonic mouse development, SSEA-1 is 
expressed from cleavage to blastocyst stage as well as in trophoblast but not in 
primitive endoderm (Solter and Knowles 1978; Gooi et al. 1981). In humans, SSEA-
1 is observed in early embryonic development just at morula stage. Its expression 
increases upon differentiation in human cells, while in the mouse cells 
differentiation leads to decreased expression (Solter and Knowles 1978; Andrews et 
al. 1982; Shevinsky et al. 1982; Andrews et al. 1984a; Fenderson et al. 1987; 
Andrews et al. 1996; Thomson et al. 1998; Reubinoff et al. 2000). Fundamental 
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changes occur in GSL biosynthesis during hPSC differentiation. At first, cells begin 
to express SSEA-1 as well as ganglioseries GSLs while losing the expression of 
globoseries. This suggests that pluripotency-specific GSL groups are generally 
replaced by neolacto-series and ganglioside structures (Liang et al. 2010; Liang et al. 
2011). Similar changes have also been described in hEC, teratocarcinoma (hTC) as 
well as mESC, indicating that it is a feature common to all embryonic cell types. 
 
2.3.5 Genetic characterization 
 
As genetic experiments cannot be carried out in the early human embryo, confirming 
the role of the key transcription factors in early embryonic development is 
impossible. Studies are limited to investigating the effect of their manipulation in 
vitro. Studies with induced pluripotent stem cells have increased our understanding 
of the mechanism of key transcription factors in early development. 
 
The transcription factors Oct4 (also known as Pou5f), Sox2, a member of the SRY-
related high mobility group -box (SOX) family and Nanog, a homeobox protein, are 
key regulators of early development. Oct4 is required to maintain the pluripotent cell 
population of the ICM and epiblast and without it, ICM and epiblast cells will 
differentiate along the trophoblastic lineage (Scholer et al. 1989; Rosner et al. 1990; 
Scholer et al. 1990a; Scholert et al. 1990b; Nichols et al. 1998). Sox2 is first found 
in the morula stage embryo and later becomes restricted to the ICM and epiblast and 
then to the germ cells. Sox2 is also expressed in the extraembryonic ectoderm and in 
the precursor cells of the developing central nervous system (Gubbay et al. 1990; 
Avilion et al. 2003). Nanog was identified as a pluripotency factor over ten years 
later than Oct4 and Sox2 (Chambers et al. 2003; Mitsui et al. 2003). Its expression is 
required at a later point than Oct4 but it is also restricted to the ICM and epiblast. 
Nanog is downregulated at the time of implantation, then re-expressed again in the 
posterior region of the post-implantation egg cylinder (Hart et al. 2004). 
 
OCT4-SOX2-NANOG-triad is central to the transcriptional regulatory hierarchy that 
specifies the identity of hPSCs.  The three factors promote pluripotency and self-
renewal through interconnected autoregulatory and feed-forward loops (Figure 9). 
These transcription factors regulate hundreds of target genes in pluripotent cells, 
indicative of their pivotal role in pluripotency. They bind to transcriptionally active 
genes that have a role in pluripotency and transcriptionally inactive genes that 
promote lineage commitment. However, the expression of this triad does not, in 
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itself, guarantee pluripotency indicating that other factors are also needed (Scholer et 
al. 1990b; Nichols et al. 1998; Avilion et al. 2003; Chambers et al. 2003; Lee et al. 
2004). 
 
Kruppel-like factor 4 (Klf 4) is another member in the pluripotency core concert. 
Klfs play critical roles in many biological processes such as proliferation, 
differentiation, proliferation, and apoptosis (Garrett-Sinha et al. 1996; Shields et al. 
1996; Rowland et al. 2005). Klf4 plays an essential role in the pluripotency and its 
overexpression inhibits differentiation of PSCs. (Li et al. 2005; Takahashi and 
Yamanaka 2006; Takahashi et al. 2007). It interacts directly with Oct4 and Sox2 and 
is required for transcriptional activation of Nanog. The highest levels of activation 
were observed when these factors were accompanied by Oct4 and Sox2, indicating 
that all four act synergistically to maintain self-renewal and pluripotency (Kim et al. 
2008; Wei et al. 2009).  
 
 
Figure 9. In hPSC cells, OCT4- SOX2-NANOG triad form a core transcriptional network. KLF4 is an 
upstream regulator of feed-forward transcription loops. Modified from Kim et al (Kim, Chu et al. 
2008).  
 
2.3.6 Genomic and Epigenetic characterization 
 
Telomerase activity is essential for continued replication in any cell line. The 
telomerase enzyme is a ribonucleoprotein that maintains telomere length. A high 
level of telomerase activity is associated with cell proliferation during embryonic 
development but also with malignant growth. Telomerase is highly expressed in 
germ cells but somatic cells do not express it. Their telomeres shorten during 
senescence. This is related to the reduction of life span by limiting the number of 
cell division. hPSCs express high levels of telomerase, which explains their ability to 
undergo practically unlimited self-renewal (Andrews et al. 1986; Thomson et al. 
1998; Reubinoff et al. 2000). 
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Somatic mutations are not an unusual phenomenon in dividing cells and they can 
generate a selective advantage, such as a greater propensity for self-renewal. Human 
ES cells as well as hiPSC were found to have a tendency to acquire changes on 
prolonged culture, commonly affecting chromosomes 12, 17, 20 and X or certain 
fragments of these chromosomes (Draper et al. 2004b; Hoffman and Carpenter 
2005a,b; Mitalipova et al. 2005; Spits et al. 2008; Mayshar et al. 2010). Especially 
the changes in chromosome 12 and 17 that seem to provide growth advantage in 
prolonged culture are also common in testicular tumors (Sandberg et al. 1996; 
Looijenga et al. 2003). It has been suggested that the actual method of passaging, 
especially trypsinization, may affect the accumulation of cytogenetic abnormalities 
(Brimble et al. 2004; Mitalipova et al. 2005). Another explanation for this 
phenomenon could be the density of colonies. The high cell density within a colony 
may predispose cells to a greater metabolic stress, which may lead to the selection of 
the cells that are more resistant to stress (Buzzard et al. 2004). 
 
The balance between self-renewal and differentiation is crucial for development and 
for the health of an individual. Epigenetics refers to the underlying mechanism of 
coordinated gene control that affects gene expression without changes in DNA 
sequence. Waddington (Waddington 1959; Waddington and Robertson 1966) 
developed a concept  “canalization”, which models the developmental status and 
epigenetic landscape. The epigenetic landscape of a cell is likely to be an indicator 
of its past and current developmental state and may predict its future potential. In 
other words, genes restrict the extent to which the environment can influence the 
phenotype. Epigenetic modifications including DNA methylation, histone 
modifications and the activities of small interfering RNAs are important for the 
expression of pluripotency-associated genes, thereby affecting pluripotency and 
differentiation (Jaenisch and Bird 2003; Hoffman and Carpenter 2005b; Richards 
2006). Recent technological advances have led to comprehensive epigenome 
reference maps and data of epigenetic modifications in mouse and human pluripotent 
cells (Meissner et al. 2008; Laurent et al. 2010; Doege et al. 2012) have significantly 
increased our understanding of ES cells and epigenetic reprogramming. However, 
the epigenetic remodelling during human development and reprogramming is still in 
the beginning.  
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2.3.7 Demonstration of pluripotency 
 
The differentiation capacity of human pluripotent cells can be studied both in vitro 
and in vivo. True pluripotent cells can be differentiated as embryoid bodies (EBs). 
EBs are compact spheres that contain loosely organized tissues that recapitulate the 
normal developmental processes of early embryonic stages and promote the cell–cell 
interaction required for cell differentiation. Through EB differentiation markers of 
each of the three germ layers can be assessed.  
 
Germ line transmission in chimeric animals is the golden standard for demonstrating 
the pluripotency of mouse embryonic stem cells. For obvious ethical reasons, the 
ability of human pluripotent stem cells to contribute to the germ line is not possible.  
The teratoma assay is the current functional standard to demonstrate the pluripotency 
of human stem cells (Adewumi et al. 2007). Teratomas are tumours containing 
differentiated elements of all three embryonic germ layers. In this functional in vivo 
pluripotency assay, the spontaneous differentiation potential of human pluripotent 
stem cells is measured after their injection into immunodeficient mice (Adewumi et 
al. 2007; Gertow et al. 2007). If the cells are pluripotent, they will form well-
differentiated tumours and sections of the tumor will show elements from all three 
germ layers (Damjanov and Solter 1974; Andrews 2002; Solter 2006). 
 
2.4 SUMMARY OF PLURIPOTENCY 
 
Pluripotency does not represent a single defined stage. In order to understand the 
distinct properties of pluripotent cells and molecular mechanisms behind these, 
global gene, glycan and protein expression profiles and epigenetic modification 
should be investigated. Table 3 summarizes the most common characteristics of 
pluripotent cells  (mES, EpiSC, hPSC and hEC) grown in vitro.  The properties of 
pluripotent stem cells from adult testes are controversial (Mizrak et al. 2010, 
Chikhovskaya et al. 2012) so these cells are not included in table 3. 
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Table 3. Properties of various pluripotent cell populations in vitro (modified from Pera and Tam 
2010). 
Response to factor mES EpiSC hPSC hEC 
LIF + - - - 
BMP4 + - - - 
Activin A and/or Nodal - + + - 
FGF 2 - + + - 
Stem cell surface markers     
SSEA-1 + + - - 
SSEA-3 - + + + 
SSEA-4 - + + + 
Tra 1-60 + + + + 
Tra 1-81 + + + + 
GCMT 2  + + + 
H-type 1 NE NE + NE 
Tra 2-49/alkaline 
phosphatase 
+ + + + 
Stem cell associated genes     
OCT4 + + + + 
NANOG + + + + 
SOX2 + + + + 
KLF4 + - + + 
REX1  - + + 
Other features     
Telomerase activity + + + + 
X-inactivation - + + + 
Developmental potential     
Teratoma formation + + + + 
Chimera formation + - NE  
+ the gene or surface marker is expressed/the indicated growth factors are required for self 
renewal/X-inactivations occur in the indicated cell type/the indicated cell type will form teratomas or 
participate in chimera formation. 
- the gene or surface marker is not expressed/the indicated growth factors are not required for self 
renewal/X-inactivations do not occur in the indicated cell type/the indicated cell type will not form 
teratomas or participate in chimera formation. 
NE the attribute is not examinated 
 
2.5 APPLICATION OF HUMAN PLURIPOTENT STEM CELLS 
 
The pluripotent stem cell field is full of possibilities. Human ES cells provide a 
unique model to study human embryonic developmental events that cannot be 
studied directly in the intact human embryos. A very significant advantage of the  
hiPS cells compared to hESC, is their potential to generate patient-specific cells 
especially for disease modelling but also autologous cell transplantation.  Due to 
their proliferation capacity and ability to differentiate into any cell types in the body, 
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hPSCs have gained a lot of attention as well.  Major efforts worldwide are currently 
focused on the application of stem cells in drug and toxicological research and 
disease modelling (Silva et al. 2008; Carvajal-Vergara et al. 2010; Moretti et al. 
2010; Hockemeyer et al. 2011; Najm et al. 2011; Hasehira et al. 2012; Lahti et al. 
2012). However, there are still many challenges to solve, particularly related to 
technical, regulatory and clinical questions. 
 
2.5.1 Therapeutic promises 
 
The world’s first, and only, clinical trial testing a hESC therapy  (oligodendrocyte 
progenitor cells derived from hESCs for spinal cord injury; Geron Corporation 
www.geron.com) was terminated in 2011 because of the economics, not for the lack 
of promise. However, the first Phase I clinical trials using hESC-based cellular 
products for eye diseases have recently been approved by the regulatory authorities 
in the USA, EU and Japan (http://stemcells.nih.gov/info/health.asp) raising hopes 
that at least some of the therapeutic promises of hPSCs will gradually be realised. 
 
Manipulation of the hPSC genome has become a routine in the last few years. The 
targeted and controlled genetic engineering with nuclease-based methods play now 
an essential role in evaluating the effects of gene defects in diseases (Hockemeyer et 
al. 2011; Sebastiano et al. 2011; Zou et al. 2011; Wang et al. 2012), and it could 
open the way to completely new approaches in regenerative medicine as well. 
2.5.1.1 Teratogenity 
In iPSC technology, the reintroduction of  “stemness genes” can have undesirable 
adverse consequences. A close relationship between pluripotency and tumorigenity 
includes the risk of tumor formation from an undifferentiated population of the 
transplanted cells or from an unstable cell population that can de-differentiate or 
transform the cells to produce cancerous cells (Carpenter et al. 2009; Knoepfler 
2009; Krizhanovsky and Lowe 2009; Wobus 2010). For instance, the potential for 
reactivation of introduced genes such as c-myc and Oct4 can increase the risk of 
cancer. These issues will need to be addressed before iPS technology can be 
transferred into clinics.  
 
The tumorigenity of pluripotent cells will be eventually overcome by direct lineage 
reprogramming of somatic cells (Ieda et al. 2010; Vierbuchen et al. 2010; 
Ambasudhan et al. 2011; Pang et al. 2011; Buganim, et al. 2012). This 
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reprogramming method could avoid pluripotent, potentially tumorigenic state and 
directly generate induced differentiated cells. Further studies are needed to 
understand consequences of direct lineage reprogramming strategies. 
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3. AIMS OF THE STUDY 
 
The aims of this thesis were to:  
 
ü investigate the capacity of human foreskin fibroblasts to support human 
embryonic stem cell self- renewal. 
 
ü characterize new Finnish hESC lines and investigate their developmental 
capacity. 
 
ü identify the N-glycan profile of human embryonic stem cells and find 
potential molecular  markers to specify the stage of differentiation of hESCs.  
 
ü develop and evaluate a single component, animal-free cell culture matrix for 
human pluripotent stem cells. 
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4. MATERIALS AND METHODS  
 
All methods used in this thesis project are briefly described here and in detail in the 
"material and methods" sections of the original articles. 
4.1 Ethical approval  
 
An informed consent form for embryo donation was signed by both partners after 
receiving an oral and written description of the study. The donors did not receive 
financial compensation. Donated embryos were received from Fertility Unit at 
Karolinska University Hospital, Huddinge, Sweden. Only embryos not suitable for 
embryo transfer or cryopreservation were cultured to blastocyst stage and used for 
derivation of hESC lines (publication I). 
In paper II, donated embryos were received from Fertility Clinic, Väestöliitto, 
Helsinki (publication II) and only frozen leftover embryos were used. The human 
embryonic stem cell lines used in this study were derived in University of Helsinki, 
and this study was approved by the ethical board of the Helsinki and Uusimaa 
district hospital (HUS). 
Human iPS cells were derived at the University of Helsinki, with the permission of 
the ethical board of the Helsinki and Uusimaa district hospital (HUS) (publication 
IV). 
4.2 Derivation of embryonic stem cell lines  
 
The isolation of the inner cell masses from blastocysts was performed using 
immunosurgery.  The zona pellucida was removed using 0.5% pronase (Sigma-
Aldrich Co. USA) and trophectoderm was then removed by immunosurgery (Solter 
and Knowles 1975; Thomson, Itskovitz-Eldor et al. 1998) The blastocyst was 
incubated with rabbit antihuman whole serum (Sigma) and guinea pig complement 
serum (Sigma), resulting in lysis of the trophectoderm.  
4.3 Human induced pluripotent stem cells  
 
Two different human iPS cell lines (FiPS 5-7 and HEL11.4) were used. FiPS 5-7 
was generated from human foreskin fibroblasts (CRL-2429; ATCC, Manassas, VA, 
USA) using retrovirus-induced overexpression of OCT4, SOX2, NANOG, and LIN-
28 (Hussein, Batada et al. 2011). 
HEL11.4 was generated from adult fibroblasts (male, 84 years old) using retrovirus-
induced overexpression of four genes: OCT4, SOX2, KLF4, and c-Myc. Cells were 
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infected with virus-containing supernatant twice at 24-h intervals. The infected cells 
were harvested and re-seeded on mitotically inactivated treated MEF layer three 
days after infection. Twenty to thirty days post-transduction ES-like colonies were 
picked, expanded, and characterized. 
 
4.4 Feeder cells  
4.4.1 Human feeder cells 
 
Human foreskin fibroblasts (hFF) (CRL-2429; ATCC, Mananas, VA, USA) were 
used as feeder cells. They were mitotically inactivated either by irradiation (40Gy) 
(publication I) or by Mitomycin C (Gibco, Life Technologies) (publications II and 
III). Approximately 15 000 cells/cm2 were plated onto dishes (NUNC or Corning) 
and left overnight to form a confluent monolayer.  
4.4.2 Mouse feeder cells 
 
ICR-strain mouse embryonic fibroblast cells (embryonic day 12.5-13.5) were used. 
They were mitotically inactivated by Mitomycin C (Gibco, Life Technologies), 
approximately 20 000 cells/cm2 were plated onto dishes (NUNC or Corning) and left 
overnight to form a confluent monolayer.  
 
4.5 Extracellular matrix coating  
4.5.1 MatrigelTM 
 
Plates coated with MatrigelTM (BD Biosciences, Bedford, MA) were prepared 
according to the manufacturer’s instructions by diluting MatrigelTM 1:200 in cold 
DMEM/F12 (Life Technologies) followed by incubation of the culture plates with 
diluted MatrigelTM at RT 2 hours or 4 ºC until used. The MatrigelTM-coated plates 
were equilibrated for one hour in room temperature before use, and excess 
MatrigelTM was removed and the plate was washed once with DMEM/F12 just 
before adding the cell suspension. 
4.5.2 ECA 
 
ECA (1mg/ml) was thawed slowly at 4ºC and diluted 1:15 in PBS. It was plated at 
5µg/cm2. The plate was incubated at 4°C overnight. Next day, the plate was washed 
twice with PBS and once with DMEM/F12, before adding the cell suspension.   
 43 
4.6 Culturing human pluripotent stem cells  
4.6.1 Culture medium 
 
Human and mouse feeder cells were cultured in DMEM with Glutamax (Gibco) 
supplemented with 10% FBS (Promocell). Media was changed to KO-DMEM media 
before transfer of hPSCs onto feeder cells. The medium used for culture and 
derivation of the stem cells on feeder cells (KO-DMEM media) consisted of 
Knockout Dulbecco’s Modified Eagle’s Medium or DMEM/F12 supplemented 
(20%) with Knockout SR, 2 mM Glutamax, 1% non-essential amino acids (all from 
Gibco, Life Technologies), 0.1mM 2-mercaptoethanol (Sigma-Aldrich) and bFGF 
(Biosource/ Life Technologies) at 6 ng/ml.  
 
To prepare mEF-conditioned media (CM-media), mEF cells were cultured in T150 
bottles and when 80-90% confluent MEF media was changed to KO-DMEM media. 
Media was collected once a day during five days, filtered, supplemented with 8ng/ml 
bFGF and frozen until use. 
 
Commercially available culture media StemPro (Life Technologies) and mTeSR1 
(Stem Cell Technologies, VA, USA) were used together with MatrigelTM (BD) or 
ECA according to manufacturer’s instruction. 
4.6.2  Passaging  
 
In early passages hPSCs were passaged mechanically by slicing small pieces of the 
colonies with a glass capillary, a surgical scalpel or a needle, and then transferred 
onto a new plate using a pipette. In publication I dispase solution (10mg/ml, 
GibcoBRL, Life Technologies) was used before slicing the colonies to loosen cells 
from feeder cells. With this passaging method the hPSCs can be expanded 1:2-1:5 
with a five to ten day interval depending on the cell line and passage number. 
 
Enzymatic passaging was performed by collagenase IV treatment (Gibco, Life 
Technologies). The culture plates were incubated with collagenase IV for three to 
seven minutes at 37 ºC until the edges of the colonies started to curl up. After 
incubation, collagenase IV was removed, the plate were gently washed twice with 
DMEM/F12 before adding fresh culture media and scraping of the colonies in small 
aggregates and transferred onto feeder- or matrix-coated plates (publication II, III, 
IV).  
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In single cell assays (publication IV) cells were dissociated using TrypleSelect 
(Gibco, Life Technologies) according to manufacturer’s description and cells were 
counted with haemocytometer. 
 
4.6.3  Cryopreservation of hPSCs 
 
Two different methods have been used in cryopreservation. Early hESC lines were 
frozen by a vitrification method in open pulled straws (LEC instruments Pty. Ltd, 
Australia) (Reubinoff et al. 2001). The undifferentiated colonies were mechanically 
cut into small pieces using a surgical scalpel or a needle and washed in cell culture 
medium. Four to eight colony pieces were transferred in Vitrification media 1 
(DMEM that contained HEPES buffer supplemented with 20% FBS, 10% DMSO 
and 10% ethylene glycol) and incubated for 1 minute, followed by 25 seconds of 
incubation in Vitrification media 2 (DMEM that contained HEPES buffer 
supplemented with 20% FBS, DMSO and ethylene glycol, and 0.5 mol/l sucrose). 
The colony pieces were then transferred into a droplet of 5µl of Vitrification media 2 
from where the colonies where loaded into the straw. The straw was immediately 
submerged into liquid nitrogen for long-term storage.  
 
In slow freezing method for larger quantities, the cells were cut out from plates 
either mechanically or enzymatically, washed once in cell culture medium and 
centrifuged 400 rpm for 4 minutes. The cell pellet was gently resuspended into 
Freezing media1 (KO-DMEM supplemented with 20% FBS). Equal amount of cold 
Freezing media 2 (Freezing media 1 with 20% DMSO) was added drop wise and cell 
suspension were moved into the cryo-vial and stored at -70% o/n. On the next day 
cryo-vials were moved into  -150 °C via liquid nitrogen. 
 
4.7 Characterization 
4.7.1 Flow Cytometry analysis (FACS) 
 
Single-cell suspensions of hPSCs were obtained by dissociation with TrypLE (Life 
Technologies) 5 min at 37°C, washed twice with cold FACS buffer (PBS 
supplemented with 5% FBS) and cell suspension was passed through an 80 µm cell 
strainer (BD Biosciences). Cells were incubated with primary antibodies (SSEA3, 
Tra 1-60, H-type1 and SSEA1) (Table 4) on ice for one hour, washed once with cold 
FACS buffer and probed with a secondary antibody for 30 min in dark on ice and 
washed once.  Control cells were incubated only with secondary antibody. The used 
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antibodies are listed in Table 4. Cells were analysed in a FACSCalibur or FASCAria 
flow cytometer and analysed with Cell Quest software (all from Becton Dickinson). 
 
Table 4. Antibodies used in characterization analysis 
 
4.7.2 Immunocytochemical Analysis 
hPSCs cultured on feeders, on MatrigelTM or on ECA-coated wells were rinsed once 
with PBS before fixation with 4% paraformaldehyde for 15 min at RT. For staining 
of nuclear markers (Oct4, Nanog, Sox2) and E-cadherin, cells were permeablized 
with Triton-X for 30 min at RT.  
Cells were blocked either with appropriate 4% serum (publication I & II) or with 
Ultra-V Block (Thermo Scientific)  (publication IV) for 10 min at room temperature. 
Primary antibodies were incubated at 4°C for overnight, washed three times with 
PBS, and secondary antibodies were incubated at room temperature for 1 hr. Wells 
were then washed with PBS and counterstained using Vectashield Mounting 
Medium with DAPI (Vector Labs). The used antibodies are listed in Table 4. 
4.7.3 Lectin Analysis 
In publication III cells were stained using lectins. The cells were incubated with 
fluorescein-labeled lectins for one hour at room temperature, washed twice with PBS 
and counterstained using Vectashield Mounting Medium with DAPI (Vector Labs). 
Specific known inhibitors were used to control the specificity of lectin binding. Cells 
were incubated with the inhibitor for one hour, washed once and stained with lectins.  
The tested lectins and their inhibitors are listed in Table 5. 
 
Primary antibody Manufacturer Secondary antibody  
SSEA-3  Millipore, Invitrogen, Stemgent Anti-Rat IgG 
Tra 1-60  Millipore, Invitrogen Anti-Mouse IgM  
H-type1  Abcam Anti-Mouse IgG 
SSEA- 1  Millipore Anti-Mouse IgM 
Oct4 Santa-Cruz Anti-Rabbit IgG 
Nanog Cell Signalling Anti-Rabbit IgG 
Sox2 Cell Signalling Anti-Rabbit IgG 
E-cadherin Cell Signalling Anti-Mouse IgG 
FOXA2 / HNF3beta (P-19) Molecular Probes, Invitrogen Anti-Goat IgG 
Anti-Human Alpha-1-Fetoprotein Molecular Probes, Invitrogen Anti-Rabbit IgG 
Anti-Human/Mouse Serum 
Albumin  
Molecular Probes, Invitrogen Anti-Mouse IgG 
CXCR4 BD Bioscience Anti-Rabbit IgG 
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Table 5. The lectins and inhibitors 
Lectin Manufacturer  Inhibitor Manufacturer 
Maackia amurensis, MAA EY Laboratories α3'-sialyllactose Kyowa Hakko Kogyo, Japan 
Pisum sativum, PSA EY Laboratories α-D-mannose methyl glycoside Sigma-Aldrich 
Ulex europaeus, UEA-I EY Laboratories L-fucose Danisco Sweeteners, Finland 
 
4.7.4 RNA isolation, reverse transcription, RT-PCR and quantitative PCR 
 
Total RNA was extracted from cells using RNA isolation kit  (either SV Total RNA 
system from Promega, NucleoSpin RNA II from Macherey & Nagel or Qiagen 
RNeasy Mini kit) according to manufacturer’s instructions. Total RNA was 
calculated using a Nano-Drop spectrophotometer and cDNA was synthesized from 
0.5-2µg of total RNA. 
In RT-PCR 100ng of cDNA was used for PCR amplification with AmpliTaq Gold 
DNA polymerase (Applied Biosystems, CA, USA). Primers used are listed in Table 
6. 
 
Table 6. RT PCR primers used. 
Primer  Sequence of 5’-primer Sequence of 3’-primer Product size 
NANOG GGAAGACAAGGTCCCAGTCA ATTGTTCCAGGTCTGGTTGC 349 bp 
OCT4 CGTGAAGCTGGAGAAGGAGAAGCTG AAGGGCCGCAGCTTACACATGTTC 245 bp 
FGF4 TCACCGATGAGTGCACGTTCA GAGGAAGTGGGTGACCTTCAT 158 bp 
STELLA CACAAATGCTCACCGAAGAA TTCGATTTCCCTGAGGACTG 182bp 
TEX14 TCCTGTTTTTGGAAGCGACT GTGGCAGCTGAACAAAGTGA 214 bp 
PIWIL2 TCTATGGGGCCATCAAGAAG CCATCCCGATCACCATTAAC 195 bp 
DAZL GGAGCTATGTTGTACCTCC CCATGTAACTAGATAAGCCAG 313 bp 
PUM2 CCAACATTCCTTGGTGAG ATCAGGACCCCAAGAAGAGG 402 bp 
C-ACTIN TGATATCCGCAAGGACCTGT GCTGGAAGGTGGACAGAGAG 200 bp 
MYOSIN TCCATGTTCGACCAGACTCA AAGCGGTCACACTGCGTGGT 335 bp 
CMP AGAGCTACAGCGTCATCGAG TCTGACACGTCCAGCGTATC  316 bp 
NF-L CAAAGAGTGAAATGGCACGA AGCGGGTGGACATCAGATAG 231 bp 
TUBULIN3β CATCCAGAGCAAGAACAGCA TCGGTGAACTCCATCTCGTC 234 bp 
ALBUMIN GCACAATGAAGTGGGTAACC CAGCAGTCAGCCATTTCACC 349 bp 
FOXA2 TGCCAGGAGCACAAGCGAGG TGTTCGTAGGCCTTGAGGTCC 290 bp 
HNF1α CAGGTCTTCACCTCAGACAC GAGGCCATCTGGGTGGAGAT  263 bp 
HNF1β ACCTTGACGAATATCCACAGC CTGTGACCACCATTGCAGATG  364 bp 
HNF6 AGGGCAGATGGAAGAGATCA TGGATGGACGCTTATTTTCC 377 bp 
PDX1 ACCAAAGCTCACGCGTGGAA CTCTCGGTCAAGTTCAACAT 191 bp 
GAPDH GTCTTCACCACCATGGAGAAGGCT TGTAGCCCAGGATGCCCTTGAGGG 529 bp 
 
In qPCR 50ng of cDNA was used with SYBR Green PCR Master Mix (Sigma 
Aldrich). Quantitative PCR was performed on an Mx3000P qPCR system 
(Stratagene) using the following conditions: 95°C for 10 min, followed by 40 cycles 
of 95°C for 20s, 56°C for 25s and 72°C for 20s. The sequences of the primers used 
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in qPCR are listed in Table 7. The expression levels of each gene were normalized to 
Cyclophilin and the relative quantification was performed using the comparative CT 
method. All PCR amplifications (both RT-PCR and qPCR) were performed in 
duplicate and replicated in at least two independent experiments. 
 
Table 7. Quantitative PCR primers used. 
Primer  Sequence of 5’-primer Sequence of 3’primer 
OCT4 TTGGGCTCGAGAAGGATGTG GTGAAGTGAGGGCTCCCATA 
NANOG GAACAATCAGGCCTGGAACAGT CGCTGATTAGGCTCCAACC 
SOX2 ACACTGCCCCTCTCACACAT TCTCTTTTGCAGCTGTCATTTG 
GOOSECOID GAGAACCTCTTCCAGGAGAC   TTCTTAAACCAGACCTCCAC 
BRACHUYRY GCATGATCACCAGCCACTG TTAAGAGCTGTGATCTCCTC 
AFP  CGCTGCAAACGATGAAGCAAG AATCTGCAATGACAGCCTCAAG 
Albumin GGAAAAGTGGGCAGCAAATGT GGTTCAGGACCACGGATAGA 
CER1 CATTGGGAGACCTGCAGGAC CCCAAAGCAAAGGTTGTTCTG 
FoxA2 (HNF-3ß) AAGACCTACAGGCGCAGCT CATCTTGTTGGGGCTCTGC 
Cyclophilin CAATGGCCAACAGAGGGAAG CCAAAAACAACATGATGCCA 
 
In PCR array analysis, RNA was isolated using Qiagen RNeasy Mini kit; cDNA was 
synthesized using RT² First Strand Kits (Qiagen). The cDNA was characterized on 
the ABI PRISM® 7000 Real-Time PCR System (Applied Biosystems) using two 
different RT2 Profiler PCR Arrays (SABioscience): Embryonic stem cells (PAHS-
081) (Table 8a) and Extracellular matrix and adhesion molecules (PAHS-013) 
(Table 8b). The resulting raw data were then analysed using the PCR Array Data 
Analysis Template. 
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Table 8a. List of 84 genes of embryonic stem cell PCR-array (SABioscience) 
 Genes/markers 
Transcription Factors Maintaining 
"Stem-ness" 
FOXD3, GATA6, GBX2, NANOG, NR5A2, NR6A1, POU5F1, SOX2, 
TFCP2L1, UTF1, ZFP42. 
Signaling Molecules Required for 
Pluripotency and Self-Renewal 
COMMD3, CRABP2, EDNRB, FGF4, FGF5, GABRB3, GAL, GRB7, HCK, 
IFITM1, IL6ST, KIT, LEFTY1, LEFTY2, LIFR, NODAL, NOG, NUMB, 
PTEN, SFRP2, TDGF1. 
Cytokines and Growth Factors FGF4, FGF5, GDF3, LEFTY1, LEFTY2, NODAL, TDGF1. 
Other Embryonic Stem Cell-Specific 
Genes  
BRIX1, CD9, DIAPH2, DNMT3B, IFITM2, IGF2BP2, LIN28A, PODXL, 
REST, SEMA3A, TERT. 
Selected Embryonic Stem Cell 
Differentiation / Lineage Markers 
FOXA2, GATA4, PTF1A (Extra-Embryonic Endoderm) 
CDX2, EOMES, GCM1, KRT1(Trophoblast) 
AFP, SERPINA1(Visceral Endoderm) 
FN1, LAMA1, LAMB1, LAMC1, SOX17 (Parietal Endoderm  
T, WT1 (Mesoderm) 
DES, MYF5, MYOD1(Muscle) 
HBB, HBZ (Blood) 
COL1A1, RUNX2 (Bone) 
NES, NEUROD1, PAX6 (Neural) 
CD34, CDH5, FLT1, PECAM1(Endothelial) 
DDX4, SYCP3 (Germ Cell) 
GCG, IAPP, INS, PAX4, PDX1, SST(Pancreas) 
Cell-Differentiation / Lineage Markers OLIG2, TAT 
 
Table 8b. List of 84 genes of extracellular matrix and adhesion molecules PCR array (SABioscience). 
 Genes 
Cell Adhesion Molecules CD44, CDH1, HAS1, ICAM1, ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, 
ITGA7, ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2, ITGB3, ITGB4, 
ITGB5, MMP14, MMP15, MMP16, NCAM1, PECAM1, SELE, SELL, SELP, 
SGCE, SPG7, VCAM1 (Transmembrane Molecules) 
 
CD44, CDH1, COL11A1, COL14A1, COL6A2, CTNND1, ICAM1, ITGA8, 
VCAM1 (Cell-Cell Adhesion) 
 
ADAMTS13, CD44, ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGA7, 
ITGA8, ITGAL, ITGAM, ITGAV, ITGB1, ITGB2, ITGB3, ITGB4, ITGB5, 
SGCE, SPP1, THBS3 (Cell-Matrix Adhesion) 
 
CNTN1, COL12A1, COL15A1, COL16A1, COL5A1, COL6A1, COL7A1, 
COL8A1, VCAN, CTGF, CTNNA1, CTNNB1, CTNND2, FN1, KAL1, 
LAMA1, LAMA2, LAMA3, LAMB1, LAMB3, LAMC1, THBS1, THBS2, 
CLEC3B, TNC, VTN (Other Adhesion Molecules) 
Extracellular Matrix Proteins COL4A2, COL7A1, LAMA1, LAMA2, LAMA3, LAMB1, LAMB3, LAMC1, 
SPARC (Basement Membrane Constituents) 
 
COL11A1, COL12A1, COL14A1, COL15A1, COL16A1, COL1A1, COL4A2, 
COL5A1, COL6A1, COL6A2, COL7A1, COL8A1, FN1, KAL1 (Collagens & 
ECM Structural Constituents) 
 
ADAMTS1, ADAMTS13, ADAMTS8, MMP1, MMP10, MMP11, MMP12, 
MMP13, MMP14, MMP15, MMP16, MMP2, MMP3, MMP7, MMP8, MMP9, 
SPG7, TIMP1 (ECM Proteases) 
COL7A1, KAL1, THBS1, TIMP1, TIMP2, TIMP3 (ECM Protease Inhibitors) 
 
VCAN, CTGF, ECM1, HAS1, SPP1, TGFBI, THBS2, THBS3, CLEC3B, TNC, 
VTN (Other ECM Molecules) 
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4.8 Pluripotency assays 
4.8.1 Embryoid body formation  
 
Briefly, on the day of passage, the undifferentiated hPSCs were treated with 
collagenase IV for 5 min and then transferred to 6-well ultra-low attachment plate 
(Corning). By culturing aggregates of hPSCs in suspension without bFGF for 7-10 
days, embryoid bodies (EBs) were formed. The presence of tissue originating from 
the three embryonic germ layers was demonstrated using immunohistochemistry for 
antigens (Table 9) of the three embryonic germ layers.  
 
Table 9. Markers used in teratoma analysis 
Antigen Germ layer/Structure 
Vimentin Mesoderm /Mesenchyme 
Desmin Mesoderm /Muscle 
Neurofilament Ectoderm/Neuron 
HNF3β Endoderm 
CK-19 Epithelium 
Ki-67 Cell proliferation 
 
4.8.2 EB derivatives, stage 3 cells 
 
Embryoid bodies were transferred onto gelatin-coated cell culture plates, cultured 
ten days in DMEM/F12 supplemented with Insulin (1mg/ml)-transferrin 
(0.55mg/ml)-Sodium Selenite (0,5 µg/ml) (ITS), Fibronectin (Sigma), L-glutamine 
and Penicillin-Streptomysin. 
4.8.3 Teratoma formation  
 
To evaluate pluripotency and study the developmental potency in vivo, we used 
severe combined immunodeficient (SCID)-beige mice (publication I) and nude mice 
(publications II, IV). Nude mice are homozygous for a mutation in the forkhead box 
N1 gene that causes hairlessness and impaired thymus development, resulting in 
immature T cells and associated immunodeficiency. 
In brief, exponentially growing hPSC lines were harvested from the culture plates 
using enzymatic splitting. Cells were washed twice in DMEM/F12 and put into a 
1.5-ml collection tube containing 30 µl of culture medium. Approximately 103 to 104 
cells were implanted under the testicular capsule. Animals were anesthetized by a 
mixture of Ketamine and Xylatsine, and Carprofen was used as painkiller during the 
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operation and day after. Animals were housed under controlled humidity, 
temperature, and light regimen, and care was consistent with institutional and 
National Institute of Health guidelines. 
Teratoma growth was followed by palpation, and after seven to eight weeks, the 
mice were sacrificed using CO2 and the teratoma was dissected out. The presence of 
tissue components of all three embryonic germ cell layers was analysed from the 
haematoxylin-eosin stained sections by routine histological analysis or using 
immunohistochemistry for marker genes (neurofilament, desmin, HNF3β) of the 
three embryonic germ layers.  
4.9 N-glycan profiling  
 
hESCs and EBs were collected mechanically, washed and stored frozen until 
analyses. The total N-glycan pool was separated by an ion-exchange step into neutral 
N-glycans and acidic N-glycans, and these two glycan fractions were analysed 
separately by MALDI–TOF mass spectrometry (Figure 10). This gives a global view 
of the N-glycan repertoire and allows comparative analysis of differentiation-
associated changes. Detailed structural analyses were achieved from the total neutral 
and acidic N-glycan pools by a combination of proton NMR spectroscopy, specific 
glycosidase digestions, and MS/MS fragmentation experiments. The glycome profile 
data was used to design glycan-specific labeling reagents. The most interesting 
glycan types were chosen to study their expression profiles by lectin histochemistry. 
 
 
Figure 10. The N-glycan profiling. A. Total N-glycan pool was enzymatically isolated from about 
100.000 cells. b. The total N-glycan pool was purified with microscale solid-phase extraction and 
divided into neutral and sialylated N-glycan fractions. The N-glycan fractions were analyzed by 
MALDI-TOF mass spectometry either in positive ion mode for neutral glycans (C) or in negative ion 
mode for sialylated glycans (D). Over one hundred N-glycan signals were detected from each cell 
type. The relative abundances of the observed glycan signals were determined based on relative 
signal intensities (Saarinen et al. 1999). 
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4.10 Population growth curve and viability  
 
In publication II, cells were dissociated with Trypsin-EDTA and 10 000 to 40 000 
cells were plated on 24-well plates. Thereafter, cells were counted using 
Hemocytometer at two time points, 24h and 48h after plating. 
 
In publication IV, cells were dissociated first by collagenase IV as described earlier 
and subsequently, an aliquot of these cells was dissociated into single cells by 
TrypleSelect. Approximately 6000 cells were plated onto a 12-well plate. Cell 
number was counted at day 3 and day 6 time points. Cells were counted using 
Hemocytometer. The viability of the dissociated cells was analysed using 
CellCounter (Invitrogen) and statistical significance was determined using student’s 
two-tailed t-test. 
 
4.11 Clonogenic assay  
 
Undifferentiated hPSCs were treated with TrypLE Select for 5 min at +37C to 
dissociate them into single cells and passed through an 80 µm cell strainer (BD). 
Cells were plated at cell density 35cells/cm2 onto ECA or MatrigelTM (BD). Media 
was changed every other day. After ten days, the number of colonies was counted.  
4.12 Colony area measurement 
 
Cells were dissociated as described above (clonogenic assay doubling) and plated 
(600 cells/cm2) onto ECA or MatrigelTM (BD).  The plates were then imaged using 
Cell IQ (CM technologies) every fifth hour. After 6 days the images were analysed 
using CellIQ Analyser program (CM technologies). 
 
4.13 Validation of binding specificity 
 
Undifferentiated hPSCs were passaged enzymatically by collagenase IV (Gibco, 
Life Technologies) and plated 1:2 on ECA coated 12-well plates.  Lactose 
monohydrate (LacH2O) (Sigma-Aldrich, 100mM), lacto-N-neoteraose (LnNT) 
(Kyowa Hakko Kogyo, 100mM) and saccharose (Sigma-Aldrich, 100mM), were 
added to culture media during passaging. The attached cells were counted after 20 
hours.  
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4.14 Targeted differentiation 
 
Human embryonic stem cell lines FES29 and H9, and iPS cell line HEL11.4 were 
cultured on ECA and MatrigelTM in mEF-conditioned medium (CM) supplemented 
with bFGF. When the cultures reached 80% confluence, the differentiation 
experiments were initiated. 
 
A modified three-step differentiation protocol for hepatocyte differentiation was 
used (Hay, Zhao et al. 2008).  Details of the protocol are illustrated in Table 10. 
 
Table 10. Hepatocyte differentiation protocol. 
DE= definitive endoderm, ActA= Activin A, NaB= Natrium butyrate, NEAA= Non essential 
aminoacids, DMSO=dimethyl sulfoxide, HGF=hepacyte growth factor, OncM= Oncostatin M 
4.15 Statistical analysis 
 
Statistical analysis were performed using a two-tailed t-test or the analysis of one-
way analysis of variance (ANOVA) by the SPSS Statistics program, followed by 
Tukeys post hoc test. In publication III, the statistical analysis of glycan score 
distribution were performed using a two-tailed  t-test with Welch’s approximation 
and a two-tailed Mann-Whitney U test. All p-values less than 0.05 were regarded as 
statistically significant. The results are expressed as ± SD or SEM. 
Stage 1. à  
The first day of DE 
induction 
 
Definitive 
endoderm 
differentiation 
Stage 2. 
Differentiation to 
Hepatic 
progenitors 
Stage 3. 
Hepatocyte maturation 
RPMI1640 +Glutamax 
B27 2% (v/v) 
Wnt3a 75 ng/ml 
ActA 100 ng/ml 
NaB 1mM 
 
RPMI1640 
+Glutamax 
B27 2% (v/v) 
ActA 100 ng/ml 
NaB 0.5 mM 
 
KO-DMEM 
KO-SR 20% (v/v) 
NEAA 1% (v/v) 
Glutamine 1mM 
βMeOH 0.1mM 
DMSO 1% (v/v) 
Leibovitz’s L15 
FBS 8.2% (v/v) 
Tryptose phosphate broth 
8.3% (v/v) 
Hydro-cortisone-21-
hemisuccinate 10µM 
Insulin 1µM 
Glutamine 2mM 
HGF 10ng/ml 
OncM 20ng/ml 
1 day 4 days 5 days 10 days 
 53 
5. RESULTS AND DISCUSSION 
 
5.1 PUBLICATION I: HUMAN FORESKIN FIBROBLASTS AS FEEDER 
CELLS IN HUMAN EBMRYONIC STEM CELL  
 
Finding the optimal xeno-free techniques to culture hESCs is important for possible 
future cell therapies. The aim of our study was to avoid mouse feeder cells in human 
embryonic stem cell culture and to find a simple and robust animal-free culture 
system. In this study we used commercially available postnatal human fibroblasts, 
derived from foreskin. 
 
Inner cell mass was isolated from five human blastocysts, and two lines, HS181 and 
HS207, were established. The donated, leftover blastocysts were evaluated using a 
scoring system based on blastocyst expansion, inner cell mass, and trophectoderm 
development (Gardner and Schoolcraft 1999). None of the blastocysts was of top 
quality. Stem cell line HS 181 was derived from expanded blastocyst with a small 
ICM and small cell number in trophectoderm (score 4BB). HS 207 was derived from 
one of the most poorly developed blastocyst used in the study; it was not expanded 
at all, the ICM was practically invisible and the cell number in trophectoderm was 
small (score 2CB). These results indicate that the blastocyst morphology does not 
directly predict the outcome of the derivation. However, more blastocysts would 
have been needed to establish the relationship between blastocyst quality and hESC 
line derivation efficacy (Strom et al. 2010).   
 
Both cell lines formed morphologically normal tightly packed colonies. HS 181 was 
cultured over nine months on hFF and was fully characterized while the 
characterization of HS 207 was only partial when the study was submitted for 
publication. HS181 cells expressed the pluripotency markers Oct4, Tra 1-60 and 
SSEA-4 as well as alkaline phosphatase, and it also maintained normal 46, XX 
karyotype. The capacity of differentiation in in vivo was demonstrated by the 
teratoma assay. Cells were cultured for 20 passages on hFF and then injected under 
the testicular capsule of SCID/beige mice. Resulting teratomas were analysed and 
they were found to contain tumour-like structures and cells from all three embryonic 
layers. 
 
The use of non-human materials bears a risk of transmitting animal derived 
pathogens so the use of human cells would be preferable over the use of mouse cells 
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as feeders. Before this study, different human cell types like adult tubal epithelial 
cells and foetal muscle and skin cells had been successfully used as feeder cells 
(Richards et al. 2002).  Obtaining those cell types is not simple. Commercially 
available human foreskin fibroblasts offer a simple way for derivation and continued 
undifferentiated human embryonic stem cell growth without xenogenic 
contamination. The result of this study was a step forward towards clinical grade 
stem cells. However, several commercially available feeder-free culture systems 
now exist (StemPro and Essential 8 (http://www.lifetechnologies.com), mTeSRTM1, 
mTeSRTM2 and TeSR™-E8™ (http://www.stemcell.com), NutriStem XF/FF 
(www.stemgent.com), Pluripro® (http://www.cellgs.com)) offering defined 
conditions for culturing even clinical grade hESCs and hiPSCs. 
 
5.2 PUBLICATION II: DICTINCT DIFFERENTIATION OF INDIVIDUAL 
HUMAN EMBRYONIC STEM CELL LINES 
 
Individual cell lines may have distinct specific genetic and/or epigenetic profiles that 
may affect their differentiation properties (Hoffman and Carpenter 2005; Hoffman et 
al. 2005; Lagarkova et al. 2006). The first aim of study II was to focus on the 
differentiation characteristics between five new Finnish embryonic stem cells lines. 
Secondly, we analyzed the mRNA expression of primordial germ cell associated 
genes in these hESC lines to test the hypothesis that embryonic stem cells might 
represent early committed primordial germ cells (PGCs) rather than epiblastic cells 
(Matsui and Okamura 2005; Zwaka and Thomson 2005). 
 
Out of 323 thawed zygotes only 83 developed to blastocyst stage and 70 inner cell 
masses were successfully isolated. The blastocysts were evaluated using a previously 
described scoring system (Gardner and Schoolcraft 1999). We derived five stable 
pluripotent hESC lines (FES 21, 22, 29, 30 and FES61). One early line (FES 11) was 
lost between passages 11 and 15. This gave a derivation success rate of 7%. 
 
Two of the lines (FES 21 and FES 22) were established on mouse feeder cells and 
three (FES 29, FES30 and FES 61) on human foreskin fibroblast, but all hESC lines 
were later cultured and analysed on both mouse and human feeder cells. We did not 
find any differences in cell or colony morphology between cell lines or between 
different types of feeder cells when the cells were passaged mechanically. Cell lines 
also expressed all the tested pluripotency markers including transcription factors 
OCT4 and NANOG and cell surface markers Tra 1-60, Tra 1-81 and SSEA-4 as well 
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as alkaline phosphatase both on mEF and hFF. However, depending on feeder type, 
we found differences in the growth rate and density of colonies. Population doubling 
time of hESC was 1,5 times higher when cultured on mFF as compared to hEF 
(Figure 11).  
 
Figure 11. Population doubling time on mEF and hFF. FES 22 cells proliferate faster on mouse 
feeder cells than on human feeder cells (mean ± SD).
Also the density of hESC colonies was much higher on mEF than on hFF and 
smaller cell clusters survived on mEF when passaging cells mechanically. When 
using enzymatic passaging, human feeder cells did not support long-term 
pluripotent cell growth.  
 
The karyotype analysis showed that culture conditions or techniques may affect 
chromosomal stability. When cells were passaged mechanically on hFFs, they 
maintained their normal karyotype in long-term culture whereas enzymatic 
passaging on mEF increased the likelihood of an abnormal karyotype. Changes 
were most often seen in chromosomes 12 and 17. Our results indicate that culture 
conditions can have significant effects on many characteristics of hESCs, like 
growth rate and genetic stability, but it remained unclear what parameters, or 
combination of parameters mostly influence these findings. The International 
Stem Cell Initiative Consortium (ISCI) analyzed 125 hESC lines (including also 
FES 21, 22, 29 and 30) and 11 induced pluripotent stem (iPS) cell lines, from 38 
laboratories worldwide at early and late passages (Adewumi et al. 2007; Amps et 
al. 2011). The tendency to chromosomal abnormalities grew during prolonged 
culture. The frequent chromosomal changes occurred in chromosomes 1, 12, 17 
and 20, representing mostly non-random chromosomal gains. This suggests that 
these chromosomes might include genes, which provide growth advance for the 
undifferentiated cells. The results indicated also that enzymatic mass-passaging 
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techniques may favor the generation of abnormalities during prolonged culture 
relative to cells passaged manually.  
 
The embryoid bodies and teratomas from established cell lines showed distinct 
differentiation propensities. FES 30 cell line produced significantly less EBs during 
seven days than other cell lines (Figure 12).  They were also less differentiated, 
showing persistence of the pluripotency marker OCT4 and lower expression of the 
tested lineage-specific markers. 
 
 
Figure 12.  Capacity of EB formation between cell lines. Fifty pieces of colonies were placed in EB 
suspension culture and the number of developing EBs counted during seven days. FES 22 and FES 29 
lines formed more EBs as compared to FES 30 (p<0.001 at day 7, mean SD, n = 7). 
 
Likewise, the teratomas derived from FES 30 were poorly developed as compared to 
the other four cell lines. Teratomas from FES 30 consisted mostly of cystic 
structures when other cell lines formed solid teratomas. The gene expression and 
histology analysis proved that FES 30 teratomas were characteristically immature 
while other cell lines produced teratomas with multi-lineage tissue. 
 
We had previously made genetic profiling for FES 21, 22, 29 and 30, and they were 
not remarkably different from each other (Skottman et al. 2005) making the 
difference in functional tests unexpected. Interestingly, FES 30 is the only female 
line and epigenetic regulation of the X chromosome in females constitutes an 
important mechanism for gene dosage compensation (Chang et al. 2006). hESCs are 
known to vary in their potential to undergo X chromosome inactivation; some 
female lines express detectable levels of X-inactive specific transcript (XIST) 
whereas other lines express low or undetectable level of XIST (Hoffman et al. 2005; 
Adewumi et al. 2007; Dvash et al. 2010; Lengner et al. 2010; Anguera et al. 2012). 
The loss of XIST expression is combined with differentiation potential of pluripotent 
stem cells (Martin et al. 1978; Dhara and Benvenisty 2004; Anguera et al. 2012). 
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Female hiPSCs with loss of XIST were reported to form poorly developed cystic 
teratomas, similar to the FES 30 teratomas in our study. The international Stem Cell 
Initiative characterized 59 hESC lines from 17 laboratories (Adewumi et al. 2007), 
including the Finnish FES 21, 22, 29 and 30 lines. In this study, all male lines 
expressed low or undetectable level of XIST but there was heterogeneity between 
female lines. In part of the XX lines, expression of XIST was very low or 
undetectable, while in the other part XIST was clearly detectable. FES 30 belonged 
to the former group and this can explain the results of differentiation in our study. 
However, it is not clear whether XIST expression is directly responsible for the 
differentiation behaviour.  
 
Our results showed that gene expression profile and cell surface pluripotent markers 
assess hESC quality but they do not predict the differentiation capacity of pluripotent 
cells. The variation in the differentiation potential of hESC lines must be carefully 
considered by those comparing various differentiation methods. Later, it has been 
verified that differences in epigenetic adaptation as well as transcriptional variation 
are common among human ESC lines as well as in iPS cell lines, and this variation 
may have a significant impact on a cell line’s utility (Allegrucci et al. 2007; 
Calvanese et al. 2008; Bock et al. 2011)  
 
In the second part of this study we analyzed mRNA expression of early germ cell-
specific and germ cell-enriched genes DAZL, STELLA, PUM2, PIWIL2, and 
TEX14 (Clark et al. 2004; Zwaka and Thomson 2005) in undifferentiated cells, EBs 
and outgrowth from EBs (stage 3 cells). Both undifferentiated stem cells and EBs 
expressed all markers but stage three cells were negative for all markers except 
TEX14 and PUM2, which showed weak expression (Table 11).
 
Table 11. Gene expression in undifferentiated stem cell lines, embryoid bodies (EBs) and plated EBs 
(Stage3).  
 OCT4 NANOG PUM2 DAZL PIWIL STELLAR TEX14 
FES lines + + + + + + + 
EBs + + + + + + + 
Stage 3  - - + - - - + 
 
Our question was whether human ES cells might actually be more closely related to 
PGCs than epiblastic cells and we noticed that undifferentiated hESC express early 
germ cell-specific genes but it would be difficult to distinguish these two cell types. 
We suggested that early germ cell associated genes could be specific markers for 
hESC cells and that they may be involved in self-renewal or they might regulate 
molecular mechanisms of early differentiation. 
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5.3 PUBLICATION III: THE N-GLYCOME OF HUMAN EMBRYONIC 
STEM CELLS 
 
The focus of study III was to characterize the N-glycan profile in undifferentiated 
hESC and its modifications during differentiation. Four hESC lines (FES 21, 22, 29 
and 30) growing on human feeders were used for glycome analysis. Embryoid bodies 
and outgrowth from EBs (stage 3 cells) were used for comparison against 
undifferentiated hESCs. Both mouse and human feeder cells, culture media and its 
supplements were analysed to exclude potential contamination sources. This showed 
that the detected major glycan structures were not present in the potential 
contamination sources and N-glycan purity in the cell samples was estimated to be at 
least 93%. 
 
5.3.1 N-glycans in hESC lines 
 
In the analysed hESC samples (approximately 100 000cells /sample), the neutral N-
glycans comprised about two third of the combined neutral and sialylated N-glycan 
pool. The mass spectrometric analysis revealed in each cell line the relative 
proportions of approximately 40 neutral glycan signals. In neutral N-glycan fraction 
the high-mannose N-glycans dominate the profile and five signals (H8N2, H9N2, 
H6N2, H7N2, and H5N2) comprised over 70% of the neutral N-glycan pool (Table 
12). The profiles were similar, 15 of the 20 most abundant neutral N-glycan signals 
were the same in all lines. 
 
The acidic N-glycan profiles of the four cell lines resembled each other even if there 
were more variation between cell lines than in the neutral N-glycan profiles. The 
complex-type N-glycans dominated the acidic N-glycan profile and all the major 
signals in this N-glycan pool contained sialic acid residues (S) (Table 12). The four 
most abundant acidic N-glycan signals contained the H5N4-core (Table 12) and they 
differed only by variable number of deoxyhexose (F) and sialic acid. The result 
showed that many of the sialylated N-glycans were multifucosylated, and comparing 
the acidic N-glycan profiles between undifferentiated and differentiated cells we 
found that complex fucosylation (F>1) was the most characteristic feature of 
undifferentiated hESCs.  
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Table 12. Fourteen most abundant mass spectrometric N-glycan signals of undifferentiated hESCs 
and embryoid bodies. 
 Neutral N-glycan      Acidic N-glycan   
Composition  %  in  
hESC 
% in  
EB 
Composition  %  in  
hESC 
% in 
    EB 
H8N2 
High-mannose 
19 13 S1H5N4F1 
Complex-type 
25 19 
 
H9N2 
High-mannose 
18 14 S1H5N4F2 
Complex-type 
11 2.9 
H6N2 
High-mannose 
16 16 S2H5N4F1 
Complex-type 
6.9 3.2 
H7N2 
High-mannose 
11 10 S1H5N4 
Complex-type 
5.0 3.6 
H5N2 
High-mannose 
8.8 12 S1H6N5F1 
Complex-type 
4.3 2.7 
H5N4F1 
Complex-type 
2.5 1.3 S1H4N5F1 
Complex-type 
2.6 3.4 
H10N2 
Glycosylated 
2.4 1.7 S1H6N5F2 
Complex-type 
2.5 0.7 
H hexose, N N-acetylhexosamine, F deoxyhexose, S N-acetylneuraminic acid 
 
The data demonstrated that hESCs prefer the production of both relatively 
unprocessed large high-mannose type N-glycans and fully prosessed biantennary 
complex-type structures. Similar findings were made from cord blood derived 
CD34+ and CD133+ hematopoietic stem cells (Hemmoranta et al. 2007) and bone 
marrow derived mesenchymal stem cells (Heiskanen et al. 2009). The high-mannose 
type N-glycans increase also upon induction of pluripotency in hiPSCs (Hasehira et 
al. 2012). 
 
 We found also N-glycans containing N-glycolylneuramic acid (G) in 
undifferentiated hESC samples. It has been shown that stem cells are able to absorb 
molecules like N-glycolylneuramic acid from their surroundings during culture, and 
incorporate them into their own cell surfaces (Martin et al. 2005; Heiskanen et al. 
2007). However, its expression decreases upon culture in the absence of animal 
products (Heiskanen et al. 2007). 
 
5.3.2 N-glycan profile changes during differentiation 
 
In order to determine whether the N-glycome undergoes changes during 
differentiation, N-glycan profiles from undifferentiated hESCs, the embryoid bodies 
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and cells further differentiated from them (stage 3 cells) were compared. 
Discrimination analysis was used to distinguish distinct sets of findings and allocate 
new findings to undifferentiated and differentiated cells. The N-glycan profiles of 
the differentiated cell types differ significantly from the profile of undifferentiated 
hESC (Figure 13). There were many signals present in hESCs and EBs that 
disappeared in stage 3 cells. The acidic N-glycan profile was modified radically 
during differentiation. The five most abundant acidic N-glycan signals were different 
in all studied cell types. The major differentiation-associated changes were in their 
monosaccharide compositions. The most characteristic feature in undifferentiated 
hESC, complex fucosylation, was gradually decreased during differentiation. 
Fucosylation is involved in many cell signalling and adhesion events. Our previous 
gene expression study (Skottman et al. 2005) demonstrated that the α1,2-
fucosyltransferase genes, FUT1 and FUT2,  were overexpressed in undifferentiated 
hESCs comparing to EBs. This correlates well with the present finding that complex 
fucosylation takes place in N-linked glycans of hESCs. This suggests that glycan 
biosynthesis is controlled differently in hESCs, EBs and stage 3 cells. Overall, 29% 
and over 40 % of sialylated N-glycans were changed at EB stage and at stage 3, 
respectively, when compared to hESCs. 
 
Figure 13. Identification of differentiation stage from the N-glycome data. To test whether the 
obtained N-glycan profiles could be used for reliable identification of hESC and differentiated cells 
even with the presence of sample-to-sample variation, a data analysis was performed. The FES29 and 
embryoid bodies derived from it (EB 29) were selected as the training group for the calculation. The 
resulting equation was applied to the other samples that served as the test group in the analysis and 
the results are described graphically. hESCs and the differentiated cell samples were clearly 
discriminated from each other by 2-tailed  Student’s t-test with Welch’s approximation (p < 0.01). 
Furthermore, the stage 3 (st.3) differentiated cell samples were separated from the EB samples by 2-
tailed Mann-Whitney U-test (p<0.05). The predicted 95% confidence intervals are shown for the 
three cell types. 
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The changes were not quite as marked among neutral N-glycans (14 % change at EB 
stage and 15 % at stage 3). In the neutral N-glycan pool, the high-mannose type N-
glycans, which present immature biosynthesis products of N-glycans (Stanley et al. 
2009), were common in all studied cell types. However, the EBs and stage 3 cells 
produced a wider variety of N-glycan types than hESCs, including low-mannose, 
hybrid-type, and monoantennary N-glycans even if the glycan profile did not change 
as much as the acidic N-glycans. Both hybrid and complex-type N-glycans have 
been suggested to have a role in development. Hybrid-type N-glycans may have 
special functions in proliferation (Schraen-Maschke and Zanetta 2003). Altogether, 
approximately one fourth of the N-glycan structures were changed when the hESCs 
differentiated into stage 3 cells.  However, the biological consequences of the 
observed glycosylation changes during differentiation are still unknown. 
 
5.3.3 Analysis of complex fucosylation  
 
In addition to MS and NMR profiling, further structural information was needed for 
the assignment of glycan structures. Terminal epitopes, such as sialic or fucose 
residues bring structural diversity to N-glycans. The α1,6 –fucosylation is the most 
common fucosylation in human N-glycans (Staudacher et al. 1999) and it was found 
also in our N-glycan profile: the most common fucose residue in both hESCs and 
EBs was the N-glycan core α1,6-Fuc structure.  However, in human N-glycans 
containing more than one fucose there should be other fucose linkages as well. 
Indeed, using exoglycosidase analysis we found that α1,2- and α1,3/4-fucosidase 
enzymes were characteristic to complex fucosylation in hESCs. The galactosidase 
assay results suggested that the fucosylated antennae could be either α1,2-
fucosylated H type 2 or α1,3-fucosylated Lewis X (Lex).  
 
5.3.4 Validation of the N-glycomic analysis 
 
Since the mass spectrometric and NMR spectometric profiling of hESC glycome 
comprised the overall cellular glycome, including intracellular glycans, further 
verification of cell surface presentation of the observed glycan structures was 
needed. Lectin proteins recognize glycans with specificity to certain glycan 
structures so we used lectins to validate our N-glycan profile data on the cell surface 
We stained hESCs using three lectins: Ulex europaeus agglutinin I (UEA I) that 
recognizes especially H type 2 (Fucα1-2Galβ1-4GlcNAc), and Maackia amurensis 
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agglutinin (MAA) recognizing α2,3-linked sialic acid containing structures, 
specifically Neu5Acα2-3Galβ1-4GlcNAc. To recognize α-mannosylated structures 
and potentially core fucosylated N-glycans, we used Pisum sativum agglutinin 
(PSA). The specificity of lectin staining was validated with specific glycan inhibitors 
(Figure 12). The experiments thus demonstrated that both complex fucosylated 
structures α2,3-sialylated LacNac and H-type 2 were abundant on the surface of 
undifferentiated hESCs.  The cell surface of hESCs was not labeled by PSA (Figure 
12) so α-mannosylated structures were not expressed on cell surface. 
 
  
Figure 12. To study localization of glycan components, hESC were grown on mouse feeder cells and 
labeled by fluorescent glycan-specific reagents selected based on analysis results. A. The hESC 
surfaces were stained by Maackia amurensis agglutinin (MAA) indicating that α2,3-sialylated 
glycans are abundant on hESC but not on MEF. B. In contrast, the hESC surfaces were not stained by 
Pisum sativum agglutinin (PSA) that recognized α-mannosylated glycans on MEF. Addition of 
competitive inhibitors blocks lectin binding. C. 3’-sialyllactose blocks MAA binding, and D-mannose 
blocks PSA binding (D). 
 
Although the biological significance of this study remained elusive, it generated a 
global picture of the N-glycans occurring in hESC glycoproteins. Taken together, the 
data indicated that there was only slight variation between cell lines, overall they 
shared about 85% of the total detected N-glycans. We also suggested that the N-
glycan profile of hESC consists of two parts, constant and variable. In the constant 
part, the major glycan types were high-mannose and biantennary complex-type N-
glycans and in the variable part the most characteristic feature was complex 
fucosylation. Changes in the monsaccharide compositions of the expressed N-
glycans suggest that glycan biosynthesis is controlled differently in hESCs and at the 
differentiation stage. 
 
Pluripotency-associated antigens on the cell surface are often glycoproteins or 
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glycolipids (Kannagi, et al. 1983a,b; Andrews et al. 1984a). Beyond those antibodies 
and lectins now widely used in monitoring the stem cell status, there is a need for 
discovering new markers as well as for further characterization of the function of the 
existing markers.  This study highlights the importance of protein glycosylation in 
hESCs and shows that they have a unique N-glycan profile, which is modified 
during differentiation. Recent data (Toyoda et al. 2011; Wang et al. 2011) together 
with this study support the idea that post-translational glycosylation of cell surface 
proteins might play a role in the regulation of transitions between pluripotent and 
differentiated states that occur during differentiation of pluripotent cells as well as 
reprogramming of somatic cells. However, further analyses of the global protein 
glycosylation status in a broad spectrum of hESCs and hiPSCs and their 
differentiated derivatives are still needed. 
 
5.4 PUBLICATION IV: LONG-TERM SELF-RENEWAL OF HUMAN 
PLURIPOTENT STEM CELL ON ERYTHRINA CRISTAGALLI LECTIN 
 
Cell surface glycans contribute to the adhesion capacity of cells and are essential for 
cellular signal transduction. In publication III (Satomaa et al. 2009) we studied 
glycan epitopes on the stem cell surface and in this study (Publication IV) we tested 
the capacity of these glycans to support self-renewal of pluripotent stem cells in long 
term culture. 
 
Based on the previously identified glycans typical for undifferentiated hESCs (paper 
III), we tested a number of lectins specific for these epitopes to support the long-
term culture of undifferentiated ESCs. Four lectins ECA (Erythrina Cristagalli 
agglutinin, binding specificity to type 2 N-acetyl-lactosamine structures), MAA 
(Maackia amurensis agglutinin, specific for α2,3-linked sialic acid), WFA (Wisteria 
floribunda agglutinin, binding preferentially to N-acetylgalactosamine in α- or β-
linkage) and PWA (Phytolacca americana agglutinin, with N-acetylglucosamine 
specificity, binding also to polylactosamine structures) were tested for their ability to 
act as a growth supporting matrix for hESC lines. Cells were attached only onto ECA 
and MAA but cells differentiated on MAA. Since the ECA lectin emerged as the 
most promising substrate, we then cultured one hESC line (FES 29) and one hiPSC 
line (HEL11.4) for over 20 passages (over three months) on ECA-coated cell culture 
dishes in mEF conditioned media, and also at least 10 passages in defined medium 
(StemPro, Life Technologies). The cells were passaged in small aggregates every 3-
4 days at a 1:3-1:5 ratio with collaganese IV and cultured in medium supplemented 
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with Pinacidil (Barbaric et al. 2010; Barbaric et al. 2011). The results showed that 
the hPSCs maintained pluripotency and proliferation capacity after prolonged culture 
equally well on ECA as on MatrigelTM (Figure 14).  
 
       ECA            MatrigelTM  
 
 
Figure 14. Pluripotent stem cell (FES 29) morphology on ECA and MatrigelTM. The images are 
captured in a live cell imaging system Cell IQ (CM-Technologies). Objective magnification 10x. 
 
Cells on ECA maintained the pluripotency markers OCT4, SOX2, NANOG and E-
cadherin as revealed by immunostaining. FACS analyses of cell surface markers 
TRA-1-60, SSEA-3, H-type 1 and SSEA-1 expression were performed on ECA and 
MatrigelTM every fifth passage. No significant differences were detected in the stem 
cell marker expression of hESCs cultured either on ECA or on MatrigelTM (Figure 
15). 
 
 
Figure 15. FACS analysis of pluripotency-associated cell surface markers after 20 passages on ECA. 
No differencies between cells growing on ECA or MatrigelTM were detected. 
 
The expression of the main pluripotency-associated genes was also 
demonstrated by quantitative-PCR. The expression of pluripotency genes 
OCT4, SOX2 and NANOG and primitive streak/early differentiation markers 
Brachyury and Goosecoid were analysed throughout 20 passages on ECA and 
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MatrigelTM. The expression levels of pluripotency genes remained similar; no 
significant differences were detected, some minor upregulation of Brachyury 
and Goosecoid occurred at later passages of FES29 cells on ECA. With the 
HEL11.4 cell line, the pluripotency genes tended to remain higher and the 
differentiation genes lower on ECA throughout the culture period. In addition, 
at passage 9 a bigger panel of key genes involved in the maintenance of 
pluripotency and the self-renewal status of embryonic stem cells was 
performed using PCR-arrays (SABiosciences). We studied also the gene 
expression profile of molecules involved in cell-to-cell and cell-to-matrix 
interactions. The mRNA expression profiles of about 80 genes related to 
pluripotency and early differentiation or ECM molecules showed no 
significant differences (over 2-fold) between cells cultured on ECA vs. 
MatrigelTM(Figure 16 A). Surprisingly, we did not see any difference (over 2-
fold) between ECA and MatrigelTM in adhesion assay (Figure 16 B). 
 
Figure 16. Gene profiles were compared between FES 29 culture 9 passages on MatrigelTM 
and on ECA. A. Embryonic stem cell array determined 84 key genes involved in the 
maintenance of pluripotency and the self-renewal status of embryonic stem cells.   B. The 
Extracellular Matrix and Cell Adhesion PCR Arrays determined the 84 gene expression 
profile of molecules involved in cell-to-cell and cell-to-matrix interactions.  Y-axis (log2) is 
the intensity ratio and X-axis is the average intensity for a given gene measured on two 
similar HTqPCR arrays. All differences were less than two-fold. 
 
Clonogenic assay or colony formation assay is an in vitro cell survival assay 
based on the ability of a single cell to grow into a colony. The pluripotent 
cells were seeded sparsely (35 cells/cm2) from ECA and MatrigelTM onto both 
ECA and MatrigelTM coated plates. Colonies were fixed with 4% 
paraformaldehyde, stained with alkaline phosphatase-solution and counted 
(Figure 17). Significant differencies were detected between matrixes. More 
than 10% of cells plated from ECA onto ECA formed colonies as counted 
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after 10 days whereas only around 6 % of cells from MatrigelTM onto 
MatrigelTM or ECA formed colonies (p<0.01, one way ANOVA).  
 
Figure 17. Clonogenic capacity on ECA and MatrigelTM. Significantly better clonogenicity on ECA 
(p<0.05, oneway ANOVA). 
 
The hPSC lines were cultured on ECA and MatrigelTM and monitored using a time-
lapse imaging system Cell-IQ® (CM-Technologies, Finland) to study colony size 
area. Each region of interest was monitored every 60 minutes during four days.  
Analysis of areas occupied by the colonies as well as cell number in the colonies 
showed no significant differences (Figure 18).  
 
 
Figure 18. FES 29 cells growing on ECA (Day1 (A), Day 2 (B), Day 4 (C)) and MatrigelTM (Day1 
(D), Day 2 (E), Day 4 (F). Cells were passaged in small clumps and cultured in live cell imaging 
system (Cell IQ, CM-technologies. Objective magnification 10x. .G. Areas of the colonies were 
analyzed in Cell IQ Analyzer program and results are shown as average size.  Y-axis is the diameter 
of colony area counted as pixels. No differencies in colony size were detected. 
 
The differentiation potential of cells growing on ECA was evaluated in vitro using 
the EB-differentiation assay and in vivo by the teratoma formation analysis. The EBs 
expressed markers from the three embryonic lineages; endoderm, ectoderm, and 
mesoderm, and structures from all these germ layers were also detected in the 
teratomas (Figure 19).  
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Figure 19. Teratoma from FES 29 growing on ECA. Cells from ectoderm (A), endoderm (B) and 
mesoderm (C) origin. Objective magnification 40x. 
 
We validated the cell-ECA binding specificity with specific inhibitors. The results 
showed that lactose monohydrate (LacH2O), composed of galactose β1,4-linked to 
glucose, and lactone-N-neotetraose (LnNT) composed of β1,4-linked galactose 
inhibited cell attachment effectively (p<0.001, between inhibitors and control) 
(Figure 20). We also used saccharide control, saccharose that is composed of 
fructose α1,1-linked to glucose. It had no inhibitory activity (p>0.6). This indicated 
that initial cell attachment to the growth surface was dependent on a specific 
interaction of the surface-bound lectin with stem cell glycan ligands.  
 
 
Figure 20. Validation of the binding specificity. Specific saccharide inhibitors lactose monohydrate 
(LacH2O) and lacto-N-neotetraose (LnNT) inhibited significantly cell attachment onto ECA 
(***,p<.001) . The control saccharide, saccharose, had no inhibitory activity 
 
In addition, we evaluated the in vitro differentiation potential of FES 29 and 
HEL11.4 cells to definitive endoderm and hepatic precursor cells on ECA. 
Definitive endoderm (DE) differentiation was verified by the gene and protein 
expression of the endoderm markers FoxA2 and Sox17, and the anterior DE marker 
Cerberus (CER1) as well as FACS analysis for the cell surface marker CXCR4. On 
top of MatrigelTM the cells formed a confluent single cell layer of typical DE cells. 
However, cells differentiated on ECA were found to detach easily from plates during 
DE induction leading to the loss of a significant proportion of cells (Figure 21). 
 68 
However, the cells remaining on the plate showed normal DE differentiation (Figure 
21).  
After five days of DMSO treatment at stage 2, the cells formed hepatic endoderm 
with alfafetoprotein (AFP) positive hepatic progenitors. During the later maturation 
stage, albumin expression increased rapidly and the cells obtained morphology 
typical of hepatocytes. However, also AFP expression continued to rise, which 
demonstrates the still immature nature of the hepatocyte-like cells. Overall, there 
were no qualitative differences between cells grown on ECA or MatrigelTM. 
 
Figure 21. Immunocytochemistry (FoxA2 green, OCT4 red) and morphology pictures of definitive 
endoderm cells. Detachment of cells from ECA matrix is visible. 
 
ECA is a fully defined cell culture matrix offering several advantages for the 
standardization of human pluripotent stem cell cultures. We demonstrated that ECA 
supports self-renewal and pluripotency both in serum-containing and in defined 
serum-free media. The expression of pluripotency markers and functional 
characteristics of cells cultured on ECA were comparable to cells on MatrigelTM. 
However, binding of the stem cells to ECA is relatively weak, which may cause 
problems at the time of passaging or during the induction of differentiation. We 
found that the use of Pinacidil (or ROCK inhibitor) at the time of passaging is 
obligatory to maintain a sufficient number of viable cells for efficient expansion. 
With the combination of ECA plus Pinacidil, the attachment and viability of 
dispersed single stem cells was better than on MatrigelTM plus Pinacidil. This 
resulted in higher clonogenic efficiency on ECA, which makes it a promising and 
cost-effective tool for the study of human pluripotent stem cell biology. 
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6. CONCLUDING REMARKS  
 
Since the isolation of the first hESC lines, a lot of effort has been put into 
understanding the molecular factors and signalling pathways in self-renewal and 
controlled differentiation of pluripotent cells. Traditional characterization of 
pluripotent stem cells means analysis of morphology, marker expression and 
developmental capacity. However, better tools would be needed to predict the 
differentiation propensity of the cell lines without time-consuming and expensive 
experimentation. Such tools may be developed on the basis of global genetic and 
epigenetic analyses. The deviation scorecard (Bock, Kiskinis et al. 2011) is an 
example of this approach, promising a strategy for the prediction of lineage 
differentiation propensity already at the undifferentiated state. In addition to 
genomics and proteomics, the complex cell surface glycan structure of the cell 
membrane may provide useful keys for the characterization of the hPSCs. 
 
The purpose of this thesis was to investigate culture conditions for hPSC lines and 
study characteristics of pluripotent stem cells and their differentiated progenies 
based on their glycan profiles. These studies provided new insights into culturing 
and characterization of stem cells. The main conclusions are: 
 
• Derivation and culture of hESC lines on human foreskin fibroblasts instead 
of foetal mouse fibroblasts represents an improvement in culture conditions 
towards clinical quality. 
 
• The derivation and characterization of the first Finnish embryonic stem cell 
lines demonstrates that human embryonic stem cells share many markers 
with primordial germ cells and these markers may be used to identify 
pluripotent stem cells. Furthermore, the results show that hESC lines differ 
in their capacity to differentiate and better tools are needed to predict cell 
lineage propensity. 
 
• Global N-glycan profiling of hESCs and their differentiated derivatives 
demonstrates specific glycan fingerprints of pluripotent stem cells and their 
early differentiation derivatives. Furthermore, the specific binding 
properties of various lectins can be utilized to reveal the glycan 
determinants on the cell surface. These results emphasize the importance of 
protein glycosylation in hPSCs and shows that systematic glycan biology 
analysis of stem cells may provide valuable tools for the analysis of 
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pluripotent stem cells.  
 
•   A platform for stem cell culture was developed using Erythrina Cristagalli 
(ECA) lectin. This method enabled high clonogenic efficiency and effective 
expansion of both hESC and hiPSC lines while maintaining characteristic 
stem cell marker expression and pluripotency comparable to the commonly 
used matrix, MatrigelTM ECA lectin is proposed as a cost-effective defined 
matrix for various studies of human pluripotent stem cells. 
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